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Abstract 
 Obesity results from expansion of white adipose tissue. The inability of 
white adipose tissue to adequately store lipids leads to ectopic deposition of 
lipids in non-adipose tissue that can lead to systemic insulin resistance. It is well 
known that insulin resistance correlates with inflammation of adipose tissue in 
obese animals and humans. Decreasing inflammation in the adipose tissue has 
been proven as a therapeutic strategy for improvement of insulin sensitivity in 
vivo. Numerous factors secreted by immune cells, including macrophages, have 
been suggested as regulating adipose tissue insulin sensitivity 
 In the first part of my thesis, I describe the role of one such factor, CD40 in 
adipose tissue inflammation. The CD40-CD40L dyad acts as co-stimulation in the 
interaction of antigen-presenting cells, such as macrophages and dendritic cells, 
with effector cells, such as T cells, in adaptive immunity.  We found that CD40 
knockout mice were smaller but surprisingly more insulin resistant and glucose 
intolerant compared to wild-type mice when fed a high fat diet. Consistent with 
their metabolic phenotype, knockout mice displayed increased adipose tissue 
inflammation with infiltration of immune cells including macrophages and T cells. 
Consistent with increased inflammation, CD40 knockout adipose tissue displayed 
decreased lipid storage. Deficiency of CD40 also led to increased lipid deposition 
in liver, which may be due to increased lipid release into circulation from the 
adipose tissue as well as increased lipid synthesis in the liver. CD40 knockout 
mice had increased hepatic insulin resistance and increased gluconeogensis 
vi
despite decreased hepatic inflammation. These findings suggest that CD40 is a 
novel regulator of adipose tissue inflammation in diet-induced obesity.  
 In the second part of this thesis we examined perivascular adipose tissue 
and brown adipose tissue for the presence of inflammation. In contrast to visceral 
adipose tissue, macrophage infiltration was absent in perivascular and brown 
adipose tissue as defined by reduced F480+ cells by flow cytometry and 
immunohistochemistry. We also found that perivascular adipose tissue was 
similar to brown adipose tissue as shown by gross morphology and gene 
expression pattern. Inflammatory gene expression was not increased in brown or 
perivascular adipose tissue in obese mice as determined by microarray gene 
expression analysis. These findings suggest that perivascular adipose tissue is 
more similar to brown adipose tissue than white adipose tissue and that both 
perivascular and brown adipose tissue are resistant to inflammation.  
 We conclude that, (1) CD40 protects against adipose tissue inflammation 
in diet-induced obesity, (2) the CD40 knockout mouse is an interesting model of 
hepatic steatosis with decreased inflammation and (3) perivascular adipose 
tissue is almost identical to brown adipose tissue in obese mice and that both are 
resistant to inflammation. 
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CHAPTER I: INTRODUCTION 
Obesity and insulin resistance 
There are more than one billion overweight adults worldwide at least 300 
million of whom are obese and these numbers are rapidly growing in the 
developed world [1]. Advances in technology and food production have led to a 
society with a plethora of high calorie food and a decreased need for physical 
labor, both of which fuel the obesity epidemic. Obesity is a complex disorder 
caused by an imbalance between energy consumption and expenditure and it 
increases the risk of developing complications such as type 2 diabetes, 
hypertension, atherosclerosis, coronary artery disease and cancer [2]. The global 
incidence of type 2 diabetes is projected to reach 350 million cases by the year 
2030, with expenditure attributed to diabetes estimated to hit 132 billion dollars in 
the US [3]. Public health efforts have largely been geared at preventing obesity 
on an individual, community and global level [4] while basic science has focused 
on reaching a better understanding of the mechanisms involved in the 
progression from simple obesity to metabolic dysfunction.  
Metabolic Syndrome describes obesity in the context of comorbidities that 
increase the risk of type 2 diabetes and cardiovascular disease. The clinical 
criteria include at least 3 of the following: elevated waist circumference, elevated 
serum triglycerides (TGs), reduced serum high density lipoprotein (HDL), 
elevated blood pressure and elevated fasting glucose. Numerous studies have 
shown that as adipose tissue expands with increasing obesity, it becomes 
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dysfunctional, but lipodystrophic mice and humans who lack adipose tissue also 
suffer from metabolic complications [5], highlighting the importance of properly 
functioning adipose tissue. Given the scope and magnitude of the obesity 
epidemic, it is particularly important to study the role of adipose tissue in 
physiological and pathological conditions.  
Insulin is a hormone produced by the pancreatic β cells and is central to 
regulating carbohydrate and lipid metabolism to keep blood glucose within a 
normal range. The liver, muscle and adipose tissue normally respond to insulin 
by taking up glucose and storing it as glycogen in the muscle and liver or TGs in 
adipocytes. Insulin also inhibits glucose production by the liver. To maintain 
metabolic health, adipocytes must balance the storage and release of lipids in 
response to the energy state. In a fasted state, adipocytes hydrolyze triglycerides 
into free fatty acids (FFA) through a process called lipolysis. In a fed state, 
adipocytes reesterify fatty acids for storage as TG [6].  
A healthy organism maintains serum glucose levels through a balance 
between the influx into the circulation from that stored in tissues and from food 
and the output from the circulation by uptake and utilization by tissues. Diabetes 
is a disorder of glucose homeostasis and is defined as fasting blood glucose 
>125 mg/dL and it is commonly associated with obesity.  Type I diabetes is an 
absence of insulin due to primary failure of insulin-producing β cells, while type II 
diabetes is a lack of sufficient insulin to maintain normoglycemia in the face of 
insulin resistance in the peripheral tissues such as muscle, liver and adipose 
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tissue [7]. With increasing obesity, the muscle, liver and adipose tissues' capacity 
to respond to insulin is diminished, and the β cells of the pancreas produce more 
insulin to maintain appropriate glucose levels in the blood. Such individuals are 
hyperinsulinemic but metabolically healthy because their blood glucose levels are 
still normal. A second event, failure of the β cells, is required for progression to 
insulin resistance and type 2 diabetes [8].  
The actions of insulin on adipose, muscle and liver, the main insulin-target 
tissues, are mediated through the insulin receptor (IR). The IR is a 
transmembrane tyrosine kinase that undergoes a conformational change upon 
stimulation, and autophosphorylation at multiple tyrosine residues [9-11]. The 
phosphorylated tyrosines recruit scaffolding proteins, called insulin receptor 
substrate (IRS) [12] proteins that further recruit downstream effector molecules 
which ultimately lead to phosphorylation and activation of Akt/Protein Kinase B 
on serine 473 by PI3K [13]. Akt/PKB plays an important role in the regulation of 
glucose and fat metabolism [14] and phosphorylates many substrates including 
Bcl-2-associated death promoter (BAD), which is important for cell survival, 
Glycogen sythase kinase 3 β (GSK3β), which regulates glycogen synthesis, and 
Forkhead box O-class (FOXO1), which controls gene expression and cell 
survival [12]. In its unphosphorylated state, FOXO1 is localized in the nucleus 
where it activates transcription of target genes. When FOXO1 is phosphorylated, 
it is excluded from the nucleus, which inhibits gluconeogenesis and adipocyte 
differentiation [15, 16]. Insulin can also activate extracellular-signal regulated 
4
kinases (ERKs), which are involved in the regulation of mitogenesis. Insulin 
promotes lipid storage in adipocytes and inhibits lipolysis by promoting fatty acid 
reesterification, and TG synthesis, as well as inhibiting fatty acid transport [14]. 
 
  
5
White adipose tissue 
White adipose tissue (WAT) is specialized for the storage of energy as 
TGs and is capable of synthesizing TGs de novo from glucose and importing 
fatty acids from the blood [3]. Fatty acids are toxic to cells and in early stages of 
overfeeding, efficient storage of TGs in adipose tissue protects other tissues from 
inappropriate lipid deposition and is key to maintaining insulin sensitivity [3]. As 
energy consumption continues to exceed use, adipose tissue grows by 
hypertrophy and hyperplasia [17]. An increase in the expression of enzymes 
involved in TG synthesis is observed early in obesity, consistent with an 
increased ability to store lipid [18], but eventually, the adipocytes’ ability to store 
lipids is perturbed and lipids are deposited in other tissues such as the liver and 
muscle, which contributes to systemic insulin resistance. WAT is also the largest 
endocrine organ, required for normal secretion of hormones called adipokines 
[3].  
In humans, WAT is located throughout the body with major intra-
abdominal depots around the omentum, intestines and perirenal areas as well as 
in subcutaneous areas such as the thighs, buttocks and abdomen [19]. There are 
minor white adipose tissue depots in other areas such as the retro-orbital space, 
extremities and in the bone marrow [19]. White adipose tissue contains 
adipocytes and the stromal vascular fraction (SVF), which contains immune cells, 
endothelial cells, fibroblasts, preadipocytes and other non-adipocyte cells. 
Adipocyte function differs with location. In humans, distribution of adipose tissue 
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affects ones’ metabolic state. Central or “apple-shaped” obesity with excess 
visceral fat is associated with increased risk of diabetes and metabolic syndrome 
whereas pear-shaped obesity with excess subcutaneous adipose tissue (SAT) is 
not [2].  Subcutaneous adipocytes release more leptin than visceral deposits [20] 
and several studies have shown that gene expression is significantly different in 
these WAT depots in mice [21] and humans [22] when compared to SAT. These 
depots are also anatomically distinct as visceral fat is drained by the portal 
system so secreted factors (adipokines, FFAs) go directly to the liver and could 
affect metabolism.  
In addition to the subcutaneous and visceral depots described above, 
WAT is also present surrounding the coronary arteries, aorta, microvasculature 
of the brain, skeletal muscle and kidney [23]. Like most WAT depots, this 
perivascular adipose tissue (PVAT) becomes inflamed in obese humans [24]. 
However, PVAT also has characteristics of brown adipose tissue (BAT), [25, 26] 
described in the next section. 
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Brown adipose tissue 
Brown adipose tissue (BAT) is a thermogenic tissue that burns energy to 
produce heat. In humans, BAT is found in the cervical, suprascapular and 
paravertebral space [27-29]. Brown adipocytes contain mitochondria that express 
uncoupling protein-1 (UCP-1), a 32 kDa protein which uncouples proton pumping 
and ATP production in oxidative phosphorylation. The proton leak produces heat 
in a process called nonshivering thermogenesis [30, 31]. The dissipation of the 
electron gradient, along with high rates of mitochondrial electron transport and 
fuel oxidation, result in the generation of heat and expenditure of large amounts 
of energy [30, 31]. Brown adipose mitochondria from UCP-1 KO mice are fully 
coupled, have decreased ATP synthesis, and do not recruit other UCP 
homologues for nonshivering thermogenesis and KO mice are cold-intolerant and 
lean [32]. Figure 1.1 illustrates the function of UCP1. 
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Figure 1.1: Molecular basis of UCP1 uncoupling in BAT. UCP1 is expressed 
at high levels in the inner membrane of BAT mitochondria. Normally, a proton 
gradient is established by the electron transport chain with a higher proton 
concentration in the intermembrane space. Passage of a proton down its 
concentration gradient is coupled to the production of ATP by ATP synthase. 
UCP1 allows the transfer of protons down their concentration gradient without 
producing ATP, thereby uncoupling oxidative phosphorylation with ATP 
production.  
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UCP-1-positive brown adipocytes have also been identified interspersed in 
skeletal muscle of mice, suggesting that ectopic brown adipocytes may also play 
a role in energy balance [33]. Histologically, brown adipocytes have a multilocular 
appearance with multiple lipid droplets, which contrasts with white adipocytes, 
which are unilocular in appearance with one lipid droplet that occupies the 
cytoplasm of the cell (Figure 1.2) [28]. BAT is most obvious in human infants and 
rodents because small animals have a larger surface area to volume ratio and a 
higher risk of hypothermia. Brown fat tissue provides heat to the bloodstream in 
response to sympathetic nerve stimuli and is, consistent with this function, 
comprised mainly of brown adipocytes, abundant vessels and nerves [25].  
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Figure 1.2: Histochemical morphology of BAT versus WAT 
Top panel: Brown adipose tissue (L) and white adipose tissue (R) specimens that 
have been stained with hemotoxylin and eosin.  Brown adipocytes have multiple 
lipid droplets while white adipocytes are spherical with one lipid droplet. Both 
images are 25x.  
Sophia Kogan, unpublished. 
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 BAT was linked to obesity when it was noted that genetically obese ob/ob 
mice had less BAT and suppressed UCP-1 expression, making them cold-
sensitive and decreasing energy expenditure [34]. Activity of human BAT tissue 
is stimulated by mild cold exposure [28] and is inversely correlated with obesity 
[27, 29]. The ablation of BAT or UCP-1 causes mice to be obese and insulin 
resistant [35-37] and deletion of the TNF-α receptor 1 (TNFR1) protects against 
obesity by increasing thermogenesis [38], suggesting that inflammation could 
play a role in the decline of BAT function in obesity. It has been observed that 
brown adipose depots "whiten" with increasing obesity and brown adipocytes 
have been shown to take on the gross morphology of white adipocytes when 
they atrophy [39].  
To generate heat for thermogenesis, BAT first uses stored lipids as 
substrate. This early phase of thermogenesis corresponds to norepinephrine 
released from sympathetic nerves activating the release of FFAs from lipid 
droplets. The stored lipids in BAT can only sustain thermogenic activity for a 
short time and the remaining fatty acids are imported into the cell and combusted 
[25]. Bartelt et al., performed a study to test whether cold exposure can improve 
fat tolerance by performing a fat tolerance test in normal or cold mice. In normal 
mice, TG levels rose following an oil bolus, but in cold mice, TG levels remained 
low due to massively increased clearance by the BAT [40]. It has been estimated 
that as little as 50 g of BAT could account for 20% of an adults’ daily expenditure 
if maximally stimulated [25]. Interestingly, transplantation of BAT reverses type 1 
12
diabetes in mice, and euglycemia is still maintained 6 months after transplant [41] 
These observations, taken together, suggest that stimulation of BAT could be a 
tool in the treatment of metabolic disease. 
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Role of the liver 
Glucose metabolism 
 The liver is a main site of sugar storage, in the form of a polymer called 
glycogen. During fasting or strenuous exercise, glycogen is broken down by 
glycogen phosphorylase and glucose is released into circulation via the insulin-
independent glucose transporter, GLUT2 [42]. Following a large meal, glucose 
reaches the liver via the portal vein and is shuttled into the cell by GLUT2. 
Glucose is then phosphorylated by glucokinase to glucose-6-phosphate (G6P), a 
central intermediate in hepatic glucose metabolism. G6P can be degraded during 
glycolysis to make ATP and NADH and the product, pyruvate, can be further 
broken down in the tricarboxylic acid cycle [42]. Alternatively, G6P can be 
diverted to the pentose phosphate shunt, which provides NADPH for de novo 
lipogenesis [42]. Therefore, in physiological conditions, the liver responds to 
dietary and hormonal cues to regulate both glucose and fat metabolism. 
 
Non-alcoholic fatty liver disease  
Non-alcoholic fatty liver disease (NAFLD) is a result of the accumulation of 
TGs in the liver and is usually associated with obesity. One population study 
found the prevalence of steatosis to be 34%, more than 90% of which was 
attributed to NAFLD [43]. The importance of metabolic parameters in NAFLD risk 
has been shown in population studies in which the prevalence of NAFLD 
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increased from 16.4% in normal weight individuals to 75.8% among the obese 
[44] and with increasing hyperglycemia [45].  
NAFLD is the major cause of abnormal liver function in the western world 
and a risk factor for non-alcoholic steatohepatitis (NASH), fibrosis and 
hepatocellular carcinoma (HCC) [43]. Simple steatosis refers to steatosis in the 
absence of histological evidence of hepatocellular damage, whereas NASH is 
steatosis in the context of inflammation and hepatocyte damage. The prevalence 
of NAFLD patients who develop NASH is only 2% but one third of those patients 
progress to fibrosis within 3 years and half progress within 6, a relatively large 
number of people given the high prevalence of NAFLD [43]. There is significant 
controversy regarding what factors are involved in NAFLD progression but 
evidence suggests that inflammation, oxidative stress and mitochondrial 
dysfunction may all contribute [46-48]. Though reductions in TG synthesis 
improve hepatic steatosis, there is evidence that they may worsen liver damage, 
indicating that lipid accumulation may be protective in early stages of obesity [49-
51].  
Once in the liver, fatty acids are esterified into TGs, which are stored in 
lipid droplets (LDs) or secreted in very low density lipoproteins (VLDL) into the 
circulation. There are four factors that contribute to NAFLD in the context of 
obesity and IR (summarized in Figure 1.3): (1) increased FFA delivery due to 
increased lipolysis from obese WAT as well as dietary FFA, (2) decreased FFA 
oxidation, (3) increased de novo lipogenesis and (4) decreased export via VLDL. 
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FFA delivery to the liver accounts for nearly two thirds of this accumulation [52] 
but lipid export from the liver might also be impaired in people with NAFLD 
because of defective incorporation of TG into apolipoprotein carrier proteins [53].  
Treatments of NAFLD are mostly aimed at modifying existing risk factors. 
Weight loss by diet and exercise or surgery has been shown to improve liver 
histology although rapid weight loss can exacerbate liver inflammation and 
fibrosis [54, 55]. Furthermore, agents that improve insulin sensitivity, such as 
metformin, pioglitazone and rosiglitazone, have been shown to improve features 
of NAFLD in observational studies [56-58]. 
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Figure 1.3: Mechanisms contributing to lipid accumulation in the liver.  
At least 4 factors contribute to fat accumulation in the liver in the context of 
obesity. (1) increased FFA delivery as the result of overnutrition and increased 
FFA liberation from WAT due to increased lipolysis. (2) Decreased FFA oxidation 
by the liver. (3) Increased hepatic de novo lipogenesis and (4) decreased export 
via VLDL (Adapted from Tilg 2008 [59]) 
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Lipogenesis 
Lipogenesis is a metabolic pathway occurring mainly in the liver that 
converts excess glucose into fatty acids, which can be esterified into TGs. A diet 
rich in carbohydrates, along with high insulin levels, stimulates lipogenesis 
whereas fasting inhibits it. The fractional contribution of lipogenesis to steatosis is 
2-5% in lean humans but can reach 26% in the context of obesity [52, 60]. 
Lipogenesis is insulin and glucose-dependent and under the control of specific 
transcription factors. Sterol regulatory element binding protein 1c (SREBP-1c) 
and carbohydrate response element binding protein (ChREBP) are transcription 
factors that regulate lipogenesis and are activated by insulin and carbohydrates, 
respectively. Insulin activates SREBP-1c by a mechanism initiated in the 
endoplasmic reticulum [61] and SREBP cleavage is also induced by endoplasmic 
reticulum (ER) stress [62].  
 
 
Hepatic insulin resistance 
The livers of obese or lipodystrophic animals are characterized by a 
phenomenon known as selective insulin resistance (summarized in Figure 1.4, 
below). This describes livers that are severely insulin resistant leading to glucose 
overproduction, which exacerbates hyperglycemia. Interestingly, insulin-
dependent lipogenesis is highly active. Hepatic levels of SREBP-1c are 
inappropriately high in the livers of obese animals [63]. The inability of insulin to 
suppress gluconeogenesis while lipogenesis is activated could reflect a 
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differential sensitivity to insulin of the signaling pathways that control these 
processes [63]. When insulin binds to its receptor, it activates Insulin receptor 
substrates 1 and 2 (IRS-1 and -2). IRS-1 and IRS-2 both activate PKB/Akt and it 
is hypothesized that lipogenesis activation is controlled by sterol-regulatory 
element-binding protein-1c (SREBP-1c) via mTORC1, while inhibition of 
gluconeogenesis is via phosphorylation and inactivation of Forkhead Box-O1 
(FOXO1), which normally activates gluconeogenesis by downregulating glucose-
6-phosphatase (G6Pase), a key gluconeogenic enzyme. It has been shown that 
insulin-stimulated expression of SREBP-1c is downregulated by rapamycin, an 
inhibitor of mTORC1, but this treatment has no effect on the insulin-mediated 
suppression of gluconeogenic genes [64]. 
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Figure 1.4: Selective insulin resistance in the liver.  
In an insulin sensitive liver (A), insulin signals through IRS-1, Akt and mTORC1 
to stimulate SREBP-1c and, therefore, lipogenesis. At the same time, insulin 
signals through IRS-2, Akt and  FOXO1, inhibiting gluconeogenesis by 
suppressing transcription of gluconeogenic genes such as G6Pase. In an insulin 
resistant liver (B), hyperinsulinemia decreases the expression of IRS-2, 
precluding the inhibition of gluconeogenesis. IRS-1 is not affected, allowing for 
lipogenesis.  
Adapted from Ferre, 2010 [63]. 
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Role of PPARγ in adipose and liver 
The differentiation of adipocytes from precursor cells with adipogenic 
potential is a complex process called adipogenesis. Peroxisome Proliferator-
activated receptor-γ (PPARγ) is an essential transcriptional regulator of 
adipogenesis and is required for the development, survival, and maintenance of 
adipose tissue [65-67]. PPARγ drives the expression of many key adipocyte 
genes such as lipoprotein lipase, perilipin and CIDEA, which ultimately direct 
adipocytes towards FFA storage in lipid droplets. Disruption of PPARγ decreases 
TG storage in adipocytes, increasing lipid distribution to skeletal muscle and liver, 
which contributes to systemic insulin resistance [3]. Thiazolidinediones (TZDs) 
are PPARγ agonists that increase insulin sensitivity in type II diabetes mellitus   
but their clinical use is limited because they increase the risk of cardiovascular 
mortality [68]. PPARγ plays a central role in the differentiation of white and brown 
fat. Mice with the dominant-negative P465L mutation in PPARγ had deficits in 
brown but not white adipose tissue [69], suggesting that brown fat may be more 
dependent on PPARγ than white, or that PPARγ regulation of these two tissues 
occurs via different mediators.   
In addition to its role in adipogenesis, PPARγ also regulates TG 
homeostasis in the liver, contributing to steatosis. Ablation of liver PPARγ 
reduces TG content but exacerbates hyperlipidemia and muscle IR [70] and 
deficiency of PPARγ in ob/ob obese mice worsens insulin resistance [71], partly 
through its action on Fat-specific protein 27 [72]. Interestingly, despite its role in 
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increasing steatosis, correlative observations suggest that PPARγ may protect 
against fibrosis [73] and may have a beneficial role for TZDs, PPARγ agonists, in 
patients with NAFLD [74, 75]. 
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 Adipose tissue as an endocrine organ: role of adipokines 
 Adipose tissue is also a source of inflammatory cytokines such as tumor 
necrosis factor-α (TNF-α), and monocyte chemoattractant protein 1 (MCP-1). 
These molecules increase immune cell trafficking into WAT and interfere with 
adipocyte function. As adipocytes hypertrophy with increasing obesity, MCP-1 is 
secreted by adipose tissue [76]. MCP-1 functions to increase macrophage 
infiltration into adipose tissue and likely contributes to the pro-inflammatory state 
of obese adipose tissue. However, the MCP-1 knockout mouse is still insulin 
resistant in diet-induced obesity, and when MCP-1 knockout monocytes are 
injected into obese mice, trafficking is reduced by only 40%, suggesting that 
other factors are also involved [77, 78]. These factors may be any of the wide 
variety of inflammatory molecules found in obese WAT including tumor necrosis 
factor-α, interleukin 6 and transforming growth factor-β [79-81]. Adipose tissue 
also secretes a number of adipokines such as leptin and adiponectin, which play 
an important role in energy balance but will not be discussed here.  
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Inflammation and metabolic disease 
The observation that obese humans and mice have increased TNF-α 
provided the first link between inflammation and obesity [81, 82].  Since then, 
many studies have shown a correlation between systemic inflammation and 
insulin resistance in humans [83, 84]. Deletion of TNF-α or its receptor, TNFR, 
protected against diet-induced obesity and insulin resistance in mice [85, 86] and 
treatment with infliximab, a TNF-α antibody improved insulin sensitivity in 
humans, who relapsed after cessation of treatment [87, 88].   
Numerous studies have shown an increase in macrophages in obese 
insulin resistant mice [89-91] as well as lipodystrophic mice [92]. Lean adipose 
tissue is 5-10% macrophages while in obese subjects macrophage content can 
be as high at 50% and macrophages are likely both a cause and consequence of 
local and chronic inflammation present in obesity [93-96]. Due to increased 
cytokines and fatty acids released from obese and/or dying adipocytes [79-81]  
macrophages infiltrate obese adipose tissue and phagocytose dying adipocytes 
and fatty acids forming crown-like structures (CLS) [97]. Macrophages are the 
most abundant immune cell present in obese adipose tissue and are a major 
source of proinflammatory molecules secreted [98]. ATMs of mice fed a high fat 
diet have a pro-inflammatory M1 phenotype while lean ATMs have an M2 anti-
inflammatory bias [90, 99] partly due to changes in recruitment [100] and this 
bias reverses when obese mice are switched back to a normal diet [101]. 
Interestingly, this phenomenon has also been observed in human adipose tissue 
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[102] before and after gastric bypass surgery [103, 104]. However, 
physiologically, macrophages exist in a spectrum of activated states which are 
influenced by factors including PPARγ [99, 105], CCR2[106], TNFα [107] and 
others.   Obese adipocytes and adipose tissue macrophages secrete MCP-1, 
TNF-α and other cytokines such as IL-1β [79-81]. These cytokines increase 
lipolysis, which further increases macrophage recruitment [80] and decrease TG 
synthesis, which leads to increased serum FFAs, which are taken up by the 
muscle and liver, impairing their insulin sensitivity.  Though most studies suggest 
a detrimental role for macrophages in obese adipose tissue, a few studies 
suggest that ATMs can behave like foam cells [90] and help adipocytes more 
effectively sequester lipids and may attenuate lipolysis [97].  
In addition to macrophages, T cells are also involved in altering adipose 
tissue function in the context of obesity by increasing macrophage infiltration and 
activation [108, 109]. T cells can be broadly divided into two categories: pro and 
anti-inflammatory. The physiological state of immune cell responses in vivo is 
much more nuanced, but CD4+ T regulatory cells and CD4+ Th2 T cells are 
typically anti inflammatory and CD8+ cytotoxic T cells, CD4+ Th1 T cells and 
CD4+ Th17 cells are pro-inflammatory in obese adipose tissue. Table 1.1 
summarizes the normal functions of T cells involved in adipose tissue 
inflammation.  
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Cell type Main function in immune response 
CD8+ Cytotoxic T cell Kills virus-­‐infected cells 
CD4+ TH1 cells Activates macrophages; provide help to B cells
for antibody production 
CD4+ TH2 cells Provide help to B cells for antibody
production, especially switching to IgE 
CD4+ TH17 cells Enhance neutrophil response 
CD4+ T regulatory cells Suppress T cell response 
 
Table 1.1: The roles of effector T cells in immune responses  
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T cells affect adipose tissue physiology in lean and obese states with an 
increase in proinflammatory CD8+, Th1 and Th17 cells and a decrease in anti-
inflammatory CD4, Th2 and Tregs observed in the adipose tissue of mice and 
humans as they go from a lean to obese state [108, 110-114]. Rag -/- mice, 
which lack functional B and T cells, gain more weight and are more glucose and 
insulin intolerant when fed HFD than wild-type mice. Reconstitution of CD4+ cells 
improves their glucose tolerance because these cells take on an anti-
inflammatory Th2 phenotype [108]. Other papers have shown that IL-17 
producing Th17 and interferon-γ-producing Th1 subsets are detrimental to insulin 
sensitivity because they decrease insulin signaling and adipogenesis while 
increasing lipolysis and IL-17-deficient mice are obese but insulin sensitive on 
HFD [115-118]. These papers, taken together, suggest that when adipose tissue 
mass expands, Tregs and Th2 cells fail to inhibit the actions of the CD8+, Th17 
and Th1 population, increasing inflammation and adipose tissue dysfunction.  
Other immune cells also play a role in adipose tissue inflammation. 
Natural killer T (NKT) cells in adipose tissue exacerbate insulin resistance in 
obese mice but may be protective in ND-fed animals [119-121]. B cells also play 
a pathogenic role in diet-induced adipose tissue inflammation. They accumulate 
in VAT in HFD mice in early stages of obesity and mice lacking B cells have 
equal adiposity but are insulin sensitive on HFD due to decreased macrophage 
and T cell activation and an absence of pathogenic IgG antibodies [122].  
Eosinophils protect against insulin resistance activating macrophages towards an 
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anti-inflammatory M2 phenotype [123] while mast and neutrophils cells 
exacerbate adipose tissue inflammation [124-126]. In addition to their role in 
inflammation, there is also evidence that immune cells become insulin resistant, 
which in turn contributes to global insulin resistance [127]. Table 1.2 summarizes 
the actions of immune cells in WAT in obesity.   
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Table 1.2: Immune cells found in adipose tissue and their roles in metabolic 
disease 
  
Cell type Number in 
adipose tissue 
with increasing 
obesity 
Effect on metabolic disease Ref 
Macrophages  in M1:M2 ratio 
 in total 
number 
Exacerbate insulin resistance 
through the secretion of 
proinflammatory cytokines (TNF-
α, IL1β, etc.) 
[90, 91, 
100, 
102, 
128] 
T cells   in CD8+:CD4+ 
ratio 
  in CD8+ 
  in Th1  
Th17 
 in Treg 
 in Th2 
CD8+, Th1 and Th17 
exacerbate insulin resistance 
and promote adipose tissue 
inflammation. Tregs and Th2 
cells decrease adipose tissue 
inflammation and decrease in 
number with increasing obesity. 
[108, 
109, 
111-
114, 
117, 
129] 
NKT cells  activation Exacerbate macrophage 
infiltration and adipose tissue 
inflammation in DIO. 
May protect against insulin 
resistance under ND conditions. 
[119-
121] 
B cells  in number Promote insulin resistance by 
activating proinflammatory 
macrophages and T cells and 
production of pathogenic IgG 
antibodies. 
[122] 
Eosinophils  in number Protect against insulin 
resistance by promoting M2 
activation of macrophages. 
Increase in eosinophils 
enhances glucose tolerance of 
obese mice. 
[123] 
Mast cells  in number Exacerbate insulin resistance by 
contributing to angiogenesis and 
apoptosis via IL-6 and IFN-γ 
production. 
[124] 
Neutrophils  in number 
transiently in early 
obesity 
Exacerbate insulin resistance by 
increasing macrophage 
infiltration and promote 
inflammation through secretion 
of elastase. 
[125, 
126] 
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Immune cells affect adipose tissue metabolism partly through the 
secretion of factors that alter insulin signaling. Tumor necrosis factor alpha (TNF-
α) is secreted by obese adipose tissue and has been shown to downregulate 
several steps in the insulin signaling cascade, leading to decreases in insulin 
receptor tyrosine kinase activity and IRS phosphorylation [130]. TNF-α stimulates 
lipolysis and subsequent release of FFAs from adipose tissue, which could 
induce insulin resistance in other organs such as the liver and skeletal muscle 
[131-133]. Interferon-γ (IFNγ) is produced by Th1 and CD8+ cytotoxic T cells. 
IFNγ increases lipolysis, downregulates adipogenesis and exacerbates insulin 
resistance. Depletion of IFNγ improves insulin sensitivity in HFD-fed mice [116, 
134]. IL17 is secreted by Th17 cells and impairs adipogenesis and glucose 
uptake by adipocytes, which further exacerbates metabolic disease [117].  Anti-
inflammatory cytokines such as IL10 and IL4 are also expressed in obese 
adipose tissue. These cytokines function to improve insulin sensitivity by 
inhibiting macrophage activation and TNF-α action [135-137]. Many other 
cytokines and chemokines are known to be expressed in obese adipose tissue 
and new ones are constantly being characterized. The integration of these 
signals maintains the metabolic state of the adipose tissue in healthy individuals 
but goes awry with increasing obesity.  
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Role of CD40 in Inflammation 
 An organism's health depends on its ability to regulate lymphocyte 
activation; inappropriate lymphocyte activation plays a role in the development of 
metabolic disease. Obese adipose tissue is characterized by acute and chronic 
inflammation with the involvement of a broad range of immune cells including T 
cells, macrophages, mast cells, eosinophils and others. These cells, and their 
interactions with each other and adipocytes have been shown to alter adipose 
tissue physiology in the context of obesity. T cells have been shown to be of 
particular importance in this process [108, 109, 111, 112].   
T cells require three signals to be activated. The first signal confers 
specificity and is the interaction of the histocompatibility (MHC) complexed to an 
antigen for which the T cell receptor (TCR) is specific. The second and third 
signals confer effector function and are co-stimulation by antigen presenting cells 
(APCs) and inflammatory cytokines.  In the absence of these additional signals, 
lymphocytes fail to respond and enter a permanent deactivated state called 
anergy or fail to develop optimal effector functions [138, 139]. Three major 
families provide the co-stimulatory signal: the B7:CD28 superfamily, the tumor 
necrosis factor (TNF) subfamily that lacks death domains, and the CD2 
superfamily. Please see Figure 1.5 for a schematic of T cell activation by APCs. 
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Figure 1.5: Major receptor ligand pairs involved in T cell activation.  
T cells recognize peptides presented on MHC class II on APCs with adhesion 
molecules strengthening the interaction and providing co-stimulation.  
APC, antigen presenting cell; Ag, antigen; MHC II, major histocompatibility 
complex class II; TCR, T cell receptor; (Adapted from Banchereau et al., 1994 
[138].  
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 CD40 is a 45-48 kDa type I transmembrane glycoprotein cell surface 
receptor that belongs to the TNF receptor family, which includes TNFR1, TNFRII, 
CD95, CD27, CD30, OX40, and 4-1BB [140]. Its action is summarized in Figure 
1.6. The gene spans 16.3 Kb of DNA and is encoded by 1.5 Kb mRNA 
transcribed from a gene on human chromosome 20 or murine chromosome 2. 
CD40 was discovered as a factor that stimulates the transition of B cells through 
the cell cycle [141] but is now known to also be expressed on the surface of 
antigen-presenting cells (APCs) such as macrophages/monocytes and  dendritic 
cells (DCs) and is an important regulator of the production of inflammatory 
mediators, cell survival and antigen presentation  [138]. It is also expressed in a 
large variety of cell types such as endothelial cells, epithelial cells, fibroblasts, 
smooth muscle cells, keratinocytes and platelets [142, 143] (Table 1.3). 
Consistent with its broad expression, antibodies blocking CD40 signaling have 
been shown to be beneficial in several disease models including transplantation, 
autoimmunity and infectious diseases [144, 145].  
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Cell type Functional consequences 
Pre B cells Proliferation, CD23 expression 
Naïve mature B cells Proliferation, differentiation, isotype switch 
Germinal center B cells Proliferation, differentiation, Fas expression, 
selection 
Plasma cells IL-6 production 
Monocytes/macrophages Cytokine secretion, NO production, 
Metalloproteinase production 
Monocyte procoagulant activity and tissue 
factor expression 
Triggering CD4+ T cell-dependent activation 
IL-12 expression 
Synovial monocytes TNF secretion 
Alveolar macrophages High-level CD40 expression in sarcoidosis 
Dendritic cells Growth and survival 
proliferation and differentiation 
Expression of costimulatory molecules 
MHC class II, CD25, CD58, CD80 (B7-
1), CD86 (B7-2), CD154 
Enhanced cytokine/chemoattractant 
production 
TNF-α, IL-8, IL-10 and IL-12 
MIP-1α, MIP-1β, RANTES 
Langerhans cells Same as dendritic cells 
CD34+ precursors Proliferation 
Development dendritic cells 
T cells Proliferation, CD25 expression cytokine 
production 
Eosinophils Enhanced survival 
GM-CSF production 
Endothelial cells  
Human umbilical vein 
endothelial cells (HUVEC) 
Upregulation of CD54, CD62E, CD106 
Increase tissue factor/thrombomodulin 
expression and proagulant activity 
T cell costimulation 
Increased production LIF, IL-6, GM-CSF 
expression of adhesion molecules such as E-
selectin, VCAM-1, ICAM-1 
Microvascular endothelial 
cells 
CD40 expression increased by HIV 
Vascular endothelial cells Increased IL-1, IL-6, IL-8 production 
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Epithelial cells  
Thymic epithelial cells GM-CSF production 
co-stimulation for clonal expansion of CD4+ 
thymocytes 
Kidney epithelial cells Cytokine/chemokine secretion; IL-6, LIF, GM-
CSF, IL-8, MCP-1, RANTES 
Keratinocytes Enhanced expression CD54, Bcl-x 
IL-8 secretion 
Carcinomas and 
transformed epithelial 
cells 
Growth inhibition/apoptosis 
Fibroblasts  
Synoviocytes Proliferation 
Cytokine production (GM-CSF, MIP1α) 
Lung fibroblasts Increased IL-6, IL-8, NF-κB 
Increased Cox-2, PGE2 
Dermal fibroblasts Increased IL-6, IL-8, NF-κB 
Thyroid fibroblasts Increased IL-6, IL-8, NF-κB 
Gingival fibroblasts Increased IL-6, IL-8 
Follicular dendritic cells Growth 
CD54 expression 
Vascular smooth muscle cells Increased MMP-1, MMP-3, MMP-9, MMP-2 
Activation ICE (IL-1β converting enzyme) 
Induction stromelysin-3 (MMP-11) 
Hepatocytes Induction of Fas-L expression 
 
Table 1.3: Cells expressing CD40 and functional consequences of in vitro 
activation (Modified from van Kooten, 2000 [146]). 
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Murine CD40 ligand (CD40L, CD154, gp39, T-BAM, TRAP) is a type II 
transmembrane protein encoded by a 2.3 Kb mRNA which is translated into a 
261 amino-acid protein. CD40L exists in both a soluble and a transmembrane 
form. The transmembrane form has a molecular weight of 39 kDa. The soluble 
form lacks the intracellular, transmembrane and part of the extracellular domains 
and has a molecular weight of 18 kDa. CD40L is expressed on activated mature 
T cells but not on resting T cells and is primarily restricted to CD4+ T cells. It is 
also expressed on dendritic cells, B cells, endothelial cells, epithelial cells, 
macrophages and others [138]. The expression of CD40L on activated T cells is 
transient and tightly regulated with expression reported as soon as 5 minutes 
after activation [147].  
 CD40 can be found on a cell’s surface as a monomer, dimer or trimer. 
Only the dimeric and trimeric forms are sufficient for signal transduction, the latter 
sending an enhanced signal [148, 149]. Binding of CD40L to CD40 causes 
trimerization of CD40 in lipid raft domains between interacting cells in order to 
propagate the signal (Figure 1.6 below). Ligation of CD40 leads to the activation 
of kinases, the expression of genes related to cell stress, the expression of new 
surface molecules, the increase or decrease of apoptosis and the further 
differentiation of immune cells [150-154]. Activation of CD40 signaling stimulates 
cells to produce cytokines and chemokines, to express adhesion molecules, 
costimulatory molecules and enzymes such as matrix metalloproteinases 
(MMPs). These molecules, summarized in Table 1.3, are involved in local 
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inflammatory and chronic inflammatory processes [142]. Expression of CD40 is 
observed starting 6-12 h following stimulation, peaks after 24 hours and persists 
for 24-72h. In contrast, CD40L expression is more transient[155]. Induction of 
CD40 expression is controlled at the transcriptional level, but inhibition by certain 
cytokines, such as TNF-β, occurs via enhanced degradation of CD40 mRNA 
[156] 
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Figure 1.6: Potential mechanism of CD40 signaling.  
Binding of CD40 on the extracellular surface of the cell causes trimerization. The 
intracellular signal is propagated via TRAF proteins. Adapted from Schonbeck, 
2001 [155]. 
  
 
  
!"#$%& ("#$%&
)!*" +,-$
./&0,1(23456(2783
!"#$%&
("#$%&
($++ &$&9%01$
!:;+$:<
(=#/>+0<&
(234 )%,&$%,?0@/1
)A
B*
)A
B*
)A
B*
C,D10+ #%01<.:;@/1
B;@E0@/1 /F
#0%D$# D$1$<
38
 CD40 signaling is essential for activation of B cells by T cell-dependent 
antigens, germinal center formation, immunoglobulin class switching, affinity 
maturation of B cells and the development of plasma and memory B cells. This is 
illustrated by Hyper-IgM syndrome, an X-linked immunodeficiency resulting from 
a mutation of CD40 or CD40L. Patients with this disease have a reduced ability 
to generate T cell dependent antibody responses, have a lack of circulating IgA, 
IgE and IgG and are unable to generate memory B cells [157]. 
 CD40 can be activated by ligands other than CD40L. Human C4b binding 
protein (C4BP) binds to CD40 on human B cells at a different site from the one 
used by CD40L. C4BP induces proliferation and isotype switching in a CD40-
dependent manner in human cells in vitro [158]. CD40 can also be stimulated by 
the 70 kDa mycobacterial heat shock protein HSP70, which stimulates 
mononuclear cells to release chemokines [159]. The in vivo significance of these 
interactions has yet to be determined. Not only can CD40 be activated by ligands 
other than CD40L, CD40L can also mediate inflammation independently of CD40 
through interaction with Mac-1/CD11b [160]. 
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CD40 role in disease processes and obesity 
 The discovery that hyper IgM syndrome was due to an alteration in the 
CD40L gene demonstrated the critical role of the CD40-CD40L dyad in humoral 
immunity [161]. CD40 and CD40L-deficient mice had a comparable phenotype 
[162-164]. Since then, CD40 signaling has been demonstrated to be important in 
both humoral and cellular immunity and not surprisingly, has been a target for 
many chronic inflammatory and autoimmune diseases such as 
neurodegenerative disorders, graft versus host reactions and neoplasias [155].  
 Both CD40 and its ligand have also been implicated in atherosclerosis, a 
chronic disease that is often associated with obesity. The cells types present in 
atherosclerotic plaques--endothelial cells, macrophages, and smooth muscle 
cells can all express CD40 and/or CD40L and are similar to the types of cells 
present in the SVF (the non-adipocyte portion of adipose tissue). Activation of 
CD40 signaling in these cells activates the expression of proinflammatory 
cytokines, adhesion molecules, matrix metalloproteinases and procoagulants, all 
of which participate in decreasing plaque stability. Atherosclerotic mice that are 
genetically deficient in CD40L or treated with an anti-CD40L antibody have 
decreased atherosclerosis on a high cholesterol diet as well as features 
associated with increased plaque stability [165, 166]. CD40L inhibition has also 
been shown to retard the progression of atherosclerotic lesions [167, 168]. 
Soluble CD40L (sCD40L) serum levels are associated with cardiovascular 
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disease [169]. There is evidence that the role of CD40L in vascular disease is not 
entirely mediated by CD40 [160, 170, 171].  
 In chronic and inflammatory disease, CD40-CD40L signaling polarizes T 
cells towards a pro-inflammatory Th1 phenotype, suggesting that CD40 signaling 
may have a detrimental effect in obesity. Lim et al measured plasma sCD40L 
levels in obese humans and found that they were higher in diabetic patients and 
that statin and aspirin use was associated with a decrease in sCD40L [172]. 
Cipollone et al also found that sCD40L was higher in diabetic humans but also 
showed that this was associated with an increase in the inflammatory state of 
endothelial cells and monocytes [173], factors that could be relevant to CD40-
CD40L signaling in obese adipose tissue. In other studies, levels of soluble 
CD40L are significantly associated with metabolic syndrome and waist 
circumference [174], while CD40 mRNA levels in adipose tissue are correlated 
with BMI [175] and sCD40L levels decreased after gastric bypass surgery in 
obese men [176]. These correlative studies in humans all suggest that the CD40-
CD40L dyad may play a role in the pathophysiology of diet-induced obesity. 
Given the detrimental role of inflammation in obesity, and the role of the 
CD40/CD40L dyad in inflammation, one may hypothesize that a mouse deficient 
in CD40 or CD40L would have improved insulin sensitivity due to decreased 
inflammation in adipose tissue. Wolf et al showed that CD40L-deficient mice on 
HFD have decreased adipose tissue B cells, macrophages and adipose tissue 
expression of MCP-1 with a concomitant increase in Tregs. Interestingly, 
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knockout mice were more glucose intolerant and insulin resistant after 8 weeks of 
HFD despite decreased inflammation in adipose tissue. Knockout mice were also 
hypoinsulinemic and had a large increase in hepatic accumulation of TGs and 
cholesterol [177]. This study is consistent with one done by Villeneuve et al which 
also showed increased steatosis in CD40L deficient mice fed an olive-oil-rich diet 
due to impaired VLDL secretion and increased lipogenesis as a result of 
increased endoplasmic reticulum stress [178]. This consistency is particularly 
remarkable because they used two completely different mouse strains (Wolf et al 
used mice on a C57BL/6J background and Villeneuve et al used BALB/c mice) 
and different diets (Wolf et al used 45% fat and Villeneuve used and olive oil 
enriched diet). A third paper by Poggi et al [179] reached a different conclusion. 
Using CD40L-/- on a C57BL/6J background fed a diet of 45% fat, the same mice 
and diet that Wolf et al used, they found that knockout mice had decreased 
hepatic steatosis and improved insulin sensitivity compared to controls. They 
also reported decreased macrophage and T cell presence in epididymal adipose 
tissue as well as a general decrease in adipose tissue inflammation [179].  
In summary, obesity is associated with chronic adipose tissue and 
systemic inflammation. Correlative studies have suggested that CD40-CD40L 
may have a role in metabolic disease in humans but studies involving CD40L 
knockout mice have been unable to elucidate the role that CD40-CD40L 
signaling plays in diet -induced obesity in mice. 
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The CD40 knockout mouse 
 Though human studies have taught us a lot about obesity and diabetes, 
they are confounded by genetic and lifestyle differences that cannot be fully 
accounted for and are observational in nature. Numerous mouse models of 
insulin resistance have been described with phenotypes ranging from embryonic 
lethality to hypoglycemia [180]. The CD40 knockout mouse was first described by 
Kawabe et al in 1994 as a mouse that could only mount an IgM response (no 
IgG, IgA or IgE) and had defective germinal center formation [164]. The original 
experiments, and many subsequent immunological studies describing the CD40 
KO mouse were done on a mouse on the BALB/c background, which is protected 
against diet-induced obesity and insulin resistance and therefore rarely used for 
metabolic studies. The CD40 KO mouse has been used primarily to study the 
role of CD40 in immunological processes such as virus infection [181] and 
cellular and humoral immunity [182-184] so little is known about its metabolic 
phenotype.  
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Specific aims 
 It is well-established that obesity is associated with increased systemic 
and adipose tissue-specific inflammation. Inflammation relies on cell-cell 
interactions that are mediated by many different molecules, one of which is the 
CD40/CD40L dyad. It has been observed that sCD40L is increased in human 
obesity, metabolic syndrome and other inflammatory diseases and CD40 
expression is increased in obese insulin resistant adipose tissue. Studies using 
CD40L knockout mice have yielded inconsistent results regarding the role of 
CD40-CD40L signaling in metabolic disease.  
 It has also been shown that different adipose depots confer a beneficial or 
detrimental risk of type 2 diabetes in the context of obesity. Unlike WAT, which is 
specialized for energy storage, BAT burns energy to produce heat by uncoupling 
oxidative phosphorylation via a protein called UCP-1 while PVAT surrounds 
vessels. The ability of a small amount of BAT to burn a lot of energy has made it 
an attractive target for the treatment of metabolic disease. Brown fat activity is 
inversely correlated with obesity in humans and BAT ablation or genetic 
disruption of UCP-1 both lead to obesity in mice. Studies have shown that brown 
adipocytes can atrophy in response to inflammatory cytokines, such as TNF-α, 
but no one has shown whether or not local inflammation in brown adipose tissue 
plays a role in type 2 diabetes.  
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 In Chapter II of this dissertation we aimed to test the hypothesis that 
CD40-deficient mice will be more insulin sensitive due to lower local and 
systemic inflammation. 
The specific aims of this study were:  
 To compare glucose and insulin tolerance in CD40-/- mice challenged with 
HFD; 
 To determine whether CD40-/- mice exhibited decreased adipose tissue 
inflammation; and 
 To determine whether CD40 deficiency will increase or decrease hepatic 
steatosis. 
 In Chapter III of this dissertation we tested the hypothesis that brown 
adipose tissue and perivascular adipose tissue become inflamed with increasing 
obesity and that BAT inflammation plays a role in metabolic disease.   
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CHAPTER II: CD40 IN MICE EXACERBATES OBESITY-INDUCED ADIPOSE 
TISSUE INFLAMMATION, HEPATIC STEATOSIS AND INSULIN RESISTANCE 
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Abstract 
 
 The pathophysiology of obesity and type 2 diabetes in rodents and 
humans is characterized by low-grade inflammation in adipose tissue and liver. 
The CD40 receptor and its ligand, CD40L, initiate immune cell signaling 
promoting inflammation, but conflicting data on CD40L null mice confound its role 
in obesity-associated insulin resistance. Here we demonstrate that CD40 
receptor deficient mice on a high fat diet display the expected decrease in 
hepatic cytokine levels, but paradoxically exhibit liver steatosis, insulin resistance 
and glucose intolerance compared to their age-matched wild type controls. 
Hyperinsulinemic-euglycemic clamp studies also demonstrated insulin resistance 
in glucose utilization by the CD40 null mice compared to wild type mice. In 
contrast to liver, adipose tissue in CD40 deficient animals harbors elevated 
cytokine levels and infiltration of inflammatory cells, particularly macrophages 
and CD8+ effector T-cells. In addition, ex vivo explants of epididymal adipose 
tissue from CD40-/- mice display elevated basal and isoproterenol-stimulated 
lipolysis, suggesting a potential increase of lipid efflux from visceral fat to the 
liver. These findings reveal that, 1) CD40 null mice represent an unusual model 
of hepatic steatosis with reduced hepatic inflammation, and 2) CD40 
unexpectedly functions in adipose tissue to attenuate its inflammation in obesity, 
thereby protecting against hepatic steatosis.  
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Introduction 
 
Obesity is often associated with type 2 diabetes, hepatic steatosis, non-
alcoholic steatohepatitis [185], cardiovascular complications [186, 187] and 
certain cancers [188, 189]. When nutrient supply exceeds demand, adipocytes 
expand by hypertrophy and hyperplasia to store excess fat in the form of 
triglycerides. As adipocytes increase in size, their ability to store fat is diminished 
and fatty acids are ectopically deposited in the liver and muscle [190, 191]. This 
transition of lipid handling is thought to cause lipotoxicity in these peripheral 
tissues, disrupting insulin signaling. Glucose uptake by skeletal muscle in 
response to insulin is impaired in this condition and hepatic gluconeogenesis is 
elevated, leading to glucose intolerance. 
Adipose tissue in obese rodents and humans has the hallmarks of chronic 
inflammation, including the involvement of T cells, macrophages and other 
immune cells [110, 112, 119, 192, 193]. During the progression to obesity, 
immune cells and the factors they secrete interact with adipocytes and alter the 
ability of adipose tissue to store fat in response to insulin. Inflammation has been 
described in obese fat [194], liver [195] and muscle [196], the three key insulin 
target tissues. Importantly, it has been shown that decreasing inflammation with 
either genetic manipulation in rodents or pharmacologic inhibition of key 
mediators of inflammation in humans [197, 198], improves insulin sensitivity. 
Although the association between obesity and inflammation is extensively 
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described, the exact mechanisms for initiation of inflammation are unknown and 
the spatial and temporal actions of the cells involved are unclear. 
The CD40-CD40L costimulatory dyad plays a critical role in regulating 
innate and adaptive immune responses. CD40 is a 48-kDa transmembrane 
glycoprotein cell surface receptor that belongs to the tumor necrosis factor 
receptor (TNFR) superfamily and is activated by binding to its ligand CD40L 
[138]. Various immune cells including macrophages, B lymphocytes, T cells, 
dendritic cells and mast cells, as well as smooth muscle cells, endothelial cells 
and activated platelets express CD40 [199]. Recent evidence indicates that the 
CD40-CD40L complex is also a potential mediator of chronic inflammation in 
obesity and its related metabolic disorders [175, 200-202], suggesting a broader 
role of CD40 in cell biology. Obese and diabetic individuals have higher levels of 
active soluble CD40L (sCD40L) in the circulation compared to lean healthy 
subjects [203] and CD40 mRNA levels in white adipose tissue were found to 
positively correlate with BMI [175]. Interruption of CD40 signaling has been 
shown to limit experimental autoimmune diseases in mice such as arthritis, lupus 
nephritis, multiple sclerosis and thyroiditis and treatment of hyperlipidemic mice 
with an anti-CD40L antibody reduced the number of macrophages, T cells and 
inflammatory markers in atherosclerotic lesions [166]. Currently, targeting CD40-
CD40L signaling is considered to be a promising strategy for effecting plaque 
stabilization in the treatment of atherosclerosis [204]. 
49
Based upon the above considerations, we anticipated that suppression of 
the CD40-CD40L signaling cascade would also reduce the deleterious 
inflammation and metabolic effects associated with obesity. In fact, the CD40-
CD40L axis has recently been implicated in the pathogenic complications of 
obesity [177-179]. However, various research groups have reported conflicting 
roles of CD40L in diet-induced obesity in mice. For example, two studies showed 
that CD40L deficiency aggravated hepatic steatosis in obesity [177, 178] while 
another study indicated that the absence of CD40L attenuated diet-induced 
steatosis [179]. Furthermore, in one study, CD40L deficiency improved insulin 
resistance [179], while in another study; lack of CD40L in mice did not ameliorate 
high fat diet-induced insulin resistance [177].  A caveat in these studies is that 
CD40L can mediate inflammation through CD40-independent mechanism by 
interacting directly with Mac-1/CD11b, which is expressed abundantly on 
macrophages and monocytes [160]. We therefore designed the present studies 
to specifically evaluate the role of the CD40-CD40L dyad in adipose tissue 
inflammation, insulin resistance and hepatic steatosis associated with diet-
induced obesity. Here we evaluated the effects of depletion of CD40 itself in 
mice, which has not been yet reported. Surprisingly, we found that CD40 
knockout (CD40-/-) mice paradoxically displayed significantly higher levels of 
adipose tissue inflammation, impaired glucose tolerance and remarkable hepatic 
steatosis without liver inflammation. These results suggest an unexpected 
primary role for CD40 in attenuating immune cell recruitment to the visceral 
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adipose tissue during the progression of diet-induced obesity. This in turn 
reduces adipocyte lipolysis, thereby protecting the liver from increased influx of 
lipid from adipose tissue and enhancing whole-body glucose tolerance.  
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Materials and Methods 
 
Animal studies 
Male CD40-/- (B6.129P2-Cd40tm1Kik/J) and control C57BL/6J mice were obtained 
from the Jackson Laboratory (Bar Harbor, ME). The background strain of 
B6.129P2-Cd40tm1Kik/J mice in this study is C57BL/6Ncr, which is maintained by 
Jackson Laboratory via sibling mating (34 generations as of Nov, 2008). Since 
the C57BL/6Ncr mouse line from NIH have been separated from the B6.129P2-
Cd40tm1K k/J mice for many generations, we therefore created littermate control 
animals for this study to avoid potential genetic drift from various C57BL/6Ncr 
sub strains or colonies. We bred B6.129P2-Cd40tm1Kik/J mice with C57BL/6J mice 
and then their F1 hybrids were used to generate knockout and wild-type 
littermates. All animals were fed standard chow diet (LabDiet PicoLab 5053, 
Purina Mills, St. Louis, MO) until 8 weeks of age and then divided into two 
groups; one was fed chow diet and the other group fed high fat diet (TD.93075, 
55/Fat, Harlan Teklad, Madison, WI, fatty acid profile as % total fat: 28% 
saturated, 30% trans, 28% monounsaturated cis, 14 % polyunsaturated cis). 
Animals were housed in the University of Massachusetts (UMass) Medical 
School Animal Medicine facility with a 12-hour light/dark cycle and given ad 
libitum access to food and water. Mice and food were weighed weekly over the 
duration of the study.  
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Intraperitoneal glucose tolerance test (GTT), insulin tolerance test (ITT) and 
pyruvate tolerance test (PTT) was performed as previously described [205]. 
Composition of total fat and lean mass was assessed by 1H-MRS-based body 
composition analysis (EchoMRI-3in1TM, EchoMRI, Houston, TX). Measurements 
of energy expenditure, respiratory exchange ratio, indirect calorimetry and 
physical activity using metabolic cages (TSE Systems, Bad Homburg, Germany) 
were done by the UMass Mouse Metabolic Phenotyping Center. All experiments 
were performed in accordance with protocols approved by the Institutional 
Animal Care and Use Committees (IACUC) at UMass Medical School. 
 
Hyperinsulinemic-euglycemic clamp studies 
The clamp study was performed at the UMass Mouse Metabolic Phenotyping 
Center. Mice fed HFD for 12 weeks were subject to an overnight fast (~15 hours) 
and a 2-hour hyperinsulinemic-euglycemic clamp was conducted in awake mice 
with a primed and continuous infusion of human insulin (150 mU/kg body weight 
priming followed by 2.5 mU/kg/min; Humulin; Eli Lilly). During the clamp, 20% 
glucose was infused at variable rates to maintain euglycemia [206]. Whole body 
glucose turnover was assessed with a continuous infusion of [3-3H] glucose and 
2-deoxy-D-[1-14C]glucose (PerkinElmer, Waltham, MA) was administered as a 
bolus (10 µCi) at 75 min after the start of clamps to measure insulin-stimulated 
glucose uptake in individual organs. At the end of the study, mice were 
anesthetized, and tissues were taken for biochemical analysis. 
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Hepatic triglyceride analyses 
Hepatic triglyceride content measurement was performed as previously 
described (11). Mice were fasted for 4 hours; total lipids were extracted from liver 
samples (50 mg) using a 2:1 mixture of chloroform and methanol. The organic 
layer was dried overnight and reconstituted in a solution containing 60% butanol 
and 40% of a 2:1 mixture of Triton-X114 and methanol. Colorimetric analyses 
were used to measure total triglyceride (Wako Diagnostics, Richmond, VA). 
 
Histology 
Liver, pancreas and epididymal white adipose tissue were dissected and fixed by 
immersion in 10% neutral buffered formalin (Sigma, St. Louis, MO) for 12 hours, 
dehydrated, cleared and then embedded in paraffin. Sections (7µm) were stained 
by hematoxylin and eosin to assess morphology. Pancreatic islets were stained 
with insulin antibody (Cell Signaling, Danvers, MA). Oil red O (Sigma) was used 
to stain neutral lipids in frozen liver sections.  
 
Real-Time quantitative RT-PCR 
RNA was extracted from homogenized liver and adipose tissue using the TRIzol 
Reagent according to manufacturer’s instructions (Invitrogen, Carlsbad, CA). 
Complementary DNA was synthesized from 1 µg of total RNA using iScript cDNA 
synthesis kit (Bio-Rad, Hercules, CA). For real-time PCR, synthesized cDNA, 
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forward and reverse primers along with the iQ SYBR Green Supermix were run 
on the CFX96 real-time PCR system (Bio-Rad). Primer sequences are available 
on request. Fold change in mRNA expression was determined using the 2-
ΔΔCT method [207], with all genes normalized to the ribosomal mRNA 36B4.  
 
Western Blotting 
Tissue pieces were homogenized in S-50 protein lysis buffer (20 mM Tris [pH 
7.2], 1% Triton X-100, 100 mM NaCl, 1 mM EDTA, 25mM sodium fluoride, 1 mM 
sodium orthovanadate, 1mM benzamidine, 1 mM phenylmethylsulfonyl fluoride, 
and 10 µg/mL of aprotinin and leupeptin) in gentleMACS M tubes (Miltenyi 
Biotec, Germany). Protein was quantified using the BCA protein assay kit 
(Thermo Scientific, Waltham, MA), resolved on a 10% SDS-PAGE gel, 
transferred to a nitrocellulose memberane, blocked with 5% non-fat milk in TBST 
(0.05% Tween 20 in Tris-buffered saline), washed with TBST and incubated with 
primary antibody overnight. The blots were washed with TBST and a horseradish 
peroxidase secondary antibody was applied. Proteins were visualized using 
Western Lightening Plus ECL (PerkinElmer, Waltham, MA). Primary antibodies 
used were Phospho-Akt (Ser473) and total Akt (Cell Signaling, Danvers, MA).  
 
Ex-vivo Lipolysis Assay in epididymal adipose tissue- explants 
Epididymal fat pads were surgically removed from male mice and washed with 
ice-cold PBS. Fat pads (~100mg, n=4/mouse) were preincubated for 1 hour in 
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140 µl DMEM (Life Technologies) containing 2% fatty acid free serum albumin 
(Sigma-Aldrich). Subsequently, fat pads were incubated in 250 µl KRH buffer 
(125 mM NaCl, 5 mM KCl, 1.8 mMCaCl2, 2.6 mM MgSO4, 5 mM Hepes, pH 7.2) 
+2% BSA (fatty acid free) with or without the presence of isoproterenol (10 µM) 
for 2 hours at 37°C. Free glycerol content was quantified for each sample in the 
medium using the Free Glycerol Determination Kit (Wako Diagnostics).  Glycerol 
release from each sample was normalized to the weight of each fat pad.  
 
Flow cytometry 
Epididymal adipose tissue was isolated from mice and treated with 2 mg/mL 
collagenase (Sigma) for 45 minutes at 37oC. Digested tissue was filtered through 
a 200 µM nylon mesh and then centrifuged at 1000 rpm for 10 min.  Pelleted 
stromal vascular fraction of adipose tissue was stained with fluorescently 
conjugated primary antibodies according to manufacturers’ instructions. Primary 
antibodies used were CD4-FITC (BD Pharmingen cat 553046), CD3-APC-Cy7 
(BD Pharmingen 1452C11), CD25-APC (eBiosciences cat 17-0251-81), CD8a-
PerCP-Cy5.5 (cat 551162), CD90-PE-Cy7 (BD Pharmingen cat 561558), CD11b-
PerCP-Cy5.5 (BD Pharmingen cat 562127), F4/80-APC (ABD Serotec), NK1.1-
APC (eBiosciences Cat 17-5941), CD19-Alexa 405 (BD Pharmingen cat 
560375), FoxP3-PE (eBiosciences 12-4774). Samples were run on a BD LSRII 
flow cytometer (BD Biosciences, San Jose, CA) and analyzed in FlowJo 
(TreeStar).  
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ELISA assay 
Blood was obtained from the tail veins of mice or via cardiac puncture and 
allowed to clot. Serum was isolated by centrifugation at 1000g for 10 min.  Mouse 
insulin ELISA kit (EMD Millipore, Billerica, MA) and Mouse sCD40L Platinum 
ELISA kit (eBioscience, San Diego, CA) were used to measure serum insulin and 
sCD40L as recommended by the manufacturer. 
 
Statistical Analysis 
Differences between groups were examined for statistical significance using the 
two-tailed Student's test or analysis of variance (ANOVA) followed by post hoc 
Bonferroni tests. The data are presented as the means ± S.E.M. P-values ≤ 0.05 
are considered significant. 
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Results 
CD40-/- mice have decreased weight, food intake and physical activity.  
 To investigate the role of CD40 in diet-induced obesity, CD40-/- mice and 
wild type (WT) controls were put on feeding regimens consisting of a high fat diet 
(HFD) or a normal diet (ND). The CD40 null mice were found to be approximately 
2 grams lighter than control mice on either diet throughout most of a 14-week 
feeding period (Figure 2.1 A). These data are consistent with a previous study on 
CD40L-/- mice (32), suggesting a common role for CD40 and CD40L in the 
regulation of energy homeostasis. Food intake of CD40-/- mice was significantly 
lower on HFD (Figure 2.1B), potentially explaining in part the decreased body 
weight (Figure 2.1A). Physical activity measurements on mice fed the HFD over 
a 24-hour period indicated that CD40-/- mice were significantly less active than 
WT mice at 8 and 14 weeks of age (0 and 6 weeks on HFD)  (Figure 2.1C). 
However, respiratory exchange ratio (RER) and energy expenditure were not 
significantly different between the two groups of mice (Figure 2.1.2).  
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Figure 2.1: CD40 deficiency alters energy homeostasis. 
(A) Growth curve of mice fed either normal diet (ND) or high-fat diet (HFD) for 14 
weeks (n = 12), * indicates statistically significant difference between WT ND vs 
CD40-/- ND groups or WT HFD vs. CD40-/- HFD groups. (B) Daily food intake of 
mice (n = 12) fed ad libitum on ND or HFD for 13 weeks. (C) Ambulatory activity 
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as estimated by infrared beam breaks over a 24-hour period for mice on HFD for 
0, 6, 12 or 16 weeks (n = 6). (D) Steady-state glucose infusion rate (GIR) for WT 
and CD40-/- mice on HFD for 16 weeks to maintain euglycemia during 
hyperinsulinemic-euglycemic clamps (n = 10). (E) 14C-2-deoxy-glucose uptake in 
visceral white adipose tissue (WAT), gastrocnemius muscle (Skeletal Muscle), 
intrascapular brown adipose tissue (BAT) and heart. The data presented are 
mean ± S.E.M. Statistically significant differences are indicated (* p<0.05, ** 
p<0.01 vs. control). 
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Figure 2.1.2: RER and heat are not altered in the absence of CD40. 
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CD40 deficiency exacerbates diet-induced insulin resistance 
 Decreased weight, food intake and activity in CD40-/- mice suggested a 
role for CD40 in whole-body metabolism. To characterize this role, we did a 
series of metabolic analyses on these mice including a hyperinsulinemic-
euglycemic glucose clamp study. CD40-/- mice on HFD showed a reduced 
steady-state glucose infusion rate (GIR) (Figure 2.1 D), suggesting that absence 
of CD40 aggravates systemic insulin resistance in obesity. We also observed 
decreased 14C-2-deoxy-glucose uptake in the brown adipose tissue (BAT) of 
CD40-/- mice with no changes of glucose uptake in the white adipose tissue or 
muscle (Figure 2.1 E). The morphology of pancreatic islets, fasting serum insulin, 
serum sCD40L, serum triglyceride (TG) and free fatty acids (FFA) were similar in 
both CD40-/- and WT mice on HFD (Figure 2.2.2). To further analyze the 
metabolic phenotype of the CD40-/- mice, we subjected them to a glucose 
tolerance test (GTT) as well as an insulin tolerance test (ITT). Despite the 
reduced body weight of CD40-/- mice on HFD, they surprisingly exhibited glucose 
intolerance (Figure 2.2 A and 2.2 E) and insulin resistance (Figure 2.2 B and 2.2 
F) compared to WT controls. To assure these phenotypes we observed are due 
to CD40 deficiency and not due to the potential differences in mouse colonies or 
substrains, we created CD40-/- mice and WT littermate control mice by breeding 
the F1 hybrids of CD40-/- (B6.129P2-Cd40tm1Kik/J) and C57BL6/J parental mice. 
These cohorts were also subjected to GTT (Figure 2.2 C and 2.2 G) and ITT 
tests (Figure 2.2 D and 2.2 H). Similar to our original findings, the      CD40-/- 
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mice were significantly more glucose intolerant and insulin resistant than 
littermate control animals.   
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Figure 2.2: CD40-/- mice fed a high fat diet are more glucose intolerant and 
insulin resistant.  
(A) Glucose tolerance test (GTT) for CD40-/- and C57BL/6J control mice (30 
weeks old) on HFD for 22 weeks (n=8). Animals were fasted overnight and 
glucose was injected intraperitoneally at a dose of 1g/kg of body weight.  (B) 
Insulin tolerance test (ITT). 31 weeks old CD40-/- and C57BL/6J control mice on 
HFD for 23 weeks (n=8) were fasted for 4 hours and injected with insulin at a 
dose of 1U/kg. (C) Glucose tolerance test (GTT) for CD40-/- and littermate control 
mice (18 weeks old) on HFD for 10 weeks (n=4). Animals were fasted overnight 
and glucose was injected intraperitoneally at a dose of 1g/kg of body weight.  (D) 
Insulin tolerance test (ITT). 18 weeks old CD40-/- and littermate control mice on 
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HFD for 10 weeks (n=4) were fasted for 4 hours and injected with 1U/kg insulin. 
(E) Area under the curve (AUC) for A. (F) AUC for B. (G) AUC for C. (H) AUC for 
D. Data are presented as mean ± SEM. Statistically significant differences 
between group WT HFD and CD40-/- HFD are indicated (*p < 0.05, ** p< 0.01, 
***p<0.001). 
  
65
 
 
 
Figure 2.2.2: CD40 deficiency does not alter pancreatic islet morphology, 
serum insulin, serum sCD40L, serum Triglycerides or serum FFA under 
HFD conditions. 
(A) Light microscopy image of pancreatic tissue treated with an anti-insulin 
primary antibody. (B) Serum insulin. (C) Serum sCD40L. (D) Serum TG. (E) 
Serum FFA. 
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CD40-/- mice develop hepatic steatosis and increased de novo lipogenesis 
in the liver.  
 Recent literatures have implicated CD40L as a protective factor against 
hepatic steatosis (43, 46), which has a strong association with insulin resistance 
(29). Since we found impaired systemic insulin sensitivity in CD40-/- mice, we 
evaluated the hepatic steatosis and hepatic insulin sensitivity in these mice. No 
difference was observed in lipid content of livers of CD40-/- mice fed ND (Figure 
2.3 C) compared to WT controls on the same diet (Figure 2.3A). CD40-/- mice on 
HFD, however, displayed clearly steatotic livers, as observed both 
macroscopically and microscopically by H&E or Oil-red O staining (Figure 2.3 D 
vs 2.3 B). To quantify this increased steatosis, we measured total hepatic 
triglycerides (TG) levels and found a 59% increase in CD40-/- mice (Figure 2.3 E). 
Elevated expression of two lipid droplet proteins, cell death-inducing DFFA-like 
effector A (CIDEA) and Fat Specific Protein 27 (FSP27) (34, 35), accompanied 
the increase in total TGs in the liver (Figure 2.3 F). These lipid droplet proteins 
are specifically expressed in steatotic livers and absent in lean livers (Figure 2.3 
F). Increased hepatic steatosis could be mediated by different pathways 
including increased dietary lipid absorption, increased de novo lipogenesis, 
increased influx of non-esterified free fatty acids (FFA) from hypertrophied 
adipose tissue or decreased very low density lipoprotein (VLDL) secretion and fat 
oxidation (7, 9). As no difference in plasma FFAs, respiratory exchange ratio 
(RER) and heat production was observed between CD40 null and WT mice 
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(Figures 2.2.2 and 2.1.2), a role for increased dietary fat absorption or impaired 
fat oxidation is unlikely the cause for the hepatic steatosis in CD40-/- mice. 
Therefore, we measured the expression of transcription factors that promote 
hepatic lipogenesis as well as genes that encode enzymes contributing to 
lipogenesis. Peroxisome proliferator-activated receptor gamma (PPARγ) and 
sterol-regulatory element-binding protein-1c (SREBP1-c), two key regulators of 
hepatic lipogenesis were both significantly elevated in the CD40-/- mice fed the 
HFD (Figure 2.3 G). Acetyl-CoA carboxylase 2 (ACC2), Long-chain-fatty-acid-
CoA ligase 1 (ACLS1) are genes both involved in de novo lipogenesis and were 
both increased in CD40-/- mice (Figure 2.3 H). These data suggest that the 
hepatic steatosis observed in CD40-/- mice is probably due to an increased de 
novo lipogenesis. 
 
68
 
Figure 2.3: CD40 protects against diet-induced hepatic steatosis and 
decreases hepatic lipogenesis.  (A-D) Macroscopic (upper left inlays) and 
microscopic examination of WT and CD40-/- mouse livers on ND or 24-week 
HFD. Representative sections are stained with hematoxylin-eosin or Oil red O 
(bottom left inlays) (Magnification: 200X). (E) Hepatic total triglycerides in WT 
and CD40-/- mice fasted for 6 hours (n=6). (F) The gene expression of lipid 
droplet proteins Cidea and FSP27 in the livers of WT and CD40-/- mice (n=6) was 
measured by qRT-PCR. (G) The expression of genes that encode lipogenic 
transcription factors and coactivators (C/ebpα, C/ebpβ, Pparγ, Srebp1c, Chrebp 
and Lxr) in the livers of HFD fed WT and CD40 -/- mice (n=6). (H) The expression 
of genes that encode enzymes (Fasn, Acc1/2, SCD1, Acsl1/4, Dgat1/2, Gyk, 
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Mttp) that promote lipogenesis in the livers of HFD fed WT and CD40 -/- mice 
(n=6). Data are presented as mean ± SEM. Statistically significant differences 
between group WT HFD and CD40-/- HFD are indicated (*p < 0.05, ** p< 0.01). 
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CD40-/- mouse livers are insulin resistant despite decreased inflammation  
 Since hepatic steatosis is correlated with hepatic insulin resistance in 
mouse and human obesity, we tested the hypothesis that CD40-/- mice on HFD 
had greater hepatic insulin resistance. We injected mice intraperitoneally with 
insulin (1mU/g) and measured Akt phosphorylation at Ser-473 as an indicator of 
hepatic insulin signaling. Compared to WT controls, CD40-/- mice on HFD for 24 
weeks exhibited 45% lower Ser-473 phosphorylation on immunoblot 
densitometry analysis (Figure 2.4 A and 2.4 B). Hepatic insulin resistance often 
results in dysregulated hepatic gluconeogenesis that contributes to glucose 
overproduction and obesity-related hyperglycemia (9). Indeed, we found that 
livers of CD40-/- mice expressed increased levels of the transcription factor 
forkhead box protein O1 (FOXO1) (Figure 2.5 A). The expression of glucose-6-
phosphatase (G6pc), a key gluconeogenic enzyme, regulated by FOXO1/PGC-
1α, was also upregulated in the livers of CD40-/- mice (Figure 2.5 A).  To test 
whether gluconeogenesis was increased in HFD-fed CD40-/- mice, a pyruvate 
tolerance test (PTT) was performed with 16-hour fasted CD40-/- and WT mice. 
We found that CD40-/- mice displayed significantly higher rate of hepatic glucose 
output by converting pyruvate into glucose (Figure 2.5 B). These data suggest 
that hepatic insulin resistance in CD40-/- mice leads to elevated levels of hepatic 
gluconeogenesis. Liver inflammation has been proposed as a link between 
hepatic steatosis and insulin resistance (39). However, in testing liver 
inflammation in CD40-/- mice, we surprisingly found that nucleotide-binding 
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domain and leucine-rich-repeat-containing protein-3 (NLRP3), interferon gamma 
(IFNγ), and interleukin-1 beta (IL-1β) were significantly decreased in CD40-/- mice 
fed HFD (Figure 2.5 C). In accordance with the lower level of inflammatory 
cytokine secretion in the livers of CD40-/- mice, the expression of macrophage 
marker, F4/80, was downregulated (Figure 2.5 C). These data indicate that the 
hepatic steatosis and insulin resistance observed in the CD40-/- mice on HFD 
occurs independently of liver inflammation.  
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Figure 2.4: CD40 deficiency exacerbates hepatic insulin resistance.  
(A) Hepatic Akt activation following acute intraperitoneal insulin injection (1U/kg, 
10 minutes).  Western blot analysis of liver extracts showing phospho (Ser473) 
AKT (pAkt) levels under control (PBS, indicated as “-”) and insulin (“+”) treated 
conditions. (B) Densitometric quantitation of pAkt/Akt ratios (n=6). Data are 
presented as mean ± SEM. Statistically significant differences between groups 
WT HFD and CD40-/- HFD are indicated (*p < 0.05, ** p< 0.01). 
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Figure 2.5: CD40-/- mice display elevated gluconeogenesis and decreased 
hepatic inflammation. 
(A) The expression of genes that encode gluconeogenic transcription factors and 
coactivators (Pgc1α, FOXO1, Hnf4α, Pepck, G6pc) in the livers of HFD fed WT 
and CD40-/- mice (n=6).  (B) Pyruvate tolerance test (PTT) for mice (32-week old) 
on HFD for 24 weeks (n=8). Animals were fasted overnight and sodium pyruvate 
was injected intraperitoneally at a dose of 2g/kg of body weight. (C) The 
expression of genes (Icam, Vcam, Nlrp3, F4/80, CD68, CD3, IFNγ, TNFα and IL-
1β) associated with inflammation in the livers of WT and CD40-/- mice (n=6). Data 
are presented as mean ± SEM. Statistically significant differences between group 
WT HFD and CD40-/- HFD are indicated (*p < 0.05, ** p< 0.01, ***p<0.001). 
  
74
CD40-/- mice exhibit increased basal lipolysis in the adipose tissue.  
 Lipolysis is a process that releases fatty acids from the adipose tissue 
through hydrolysis of triglyceride stores. Decreased adipose tissue mass and the 
associated lipolysis have been correlated with hepatic steatosis (7), thus we 
examined the adipose tissue mass and lipolytic rate of HFD-fed WT and CD40-/- 
mice. There was no statistically significant difference in the percent of lean 
(Figure 2.6 A) or fat mass (Figure 2.6 B) between CD40-/- mice and WT controls. 
However, when examined histologically (Figure 2.6 C), epididymal adipose tissue 
from CD40-/- mice had increased numbers of crown-like structures (CLS). CLS 
are characterized by infiltrated immune cells, especially macrophages, 
surrounding necrotic adipocytes (28) and are a hallmark of adipose tissue 
inflammation, which is associated with increased lipolysis. Indeed, higher basal 
lipolytic activity was observed in the epididymal adipose tissue from CD40-/- mice 
when compared with the same adipose tissue from WT mice (Figure 2.6 D). 
These data suggest that increased adipose tissue lipolysis providing increased 
fatty acid flux to the liver could be a mechanism by which CD40-/- mice develop 
hepatic steatosis. 
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Figure 2.6: CD40-/- mice have increased immune cell infiltration in adipose 
tissue as well as elevated adipose tissue lipolysis.  
(A) lean mass and (B) fat mass in WT and CD40-/- mice fed HFD was measured 
by magnetic resonance imaging (MRI) analysis as a percentage of total mass 
over an 11-week period (n=10). (C) Representative sections of the epididymal 
adipose tissue from ND and HFD fed WT and CD40-/- mice were stained with 
hematoxylin-eosin. Arrows indicate crown-like structures. (Magnification: 200X) 
(D) Ex vivo lipolysis assay on epididymal adipose tissue explants from HFD fed 
WT and CD40-/- mice (n=6).  Adipose tissues were incubated in phenol red-free 
and serum-free KRH buffer. Glycerol content in the medium was assayed as an 
index of lipolysis. Epididymal fat pads lipolysis was measured at basal or 
following stimulation with 10µM isoproterenol for 2 hours at 37°C. Data are 
presented as mean ± SEM. Statistically significant differences between mouse 
group WT HFD and CD40-/- HFD are indicated (*p < 0.05). 
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CD40 depletion increases adipose tissue inflammation.  
 Since increased lipolysis and CLS in adipose tissue are often associated 
with increased infiltration of macrophages and other proinflammatory cells, we 
analyzed epididymal fat pads from HFD-fed mice for the presence of 
inflammation. First, we measured the presence of cells expressing macrophage 
surface markers F4/80 and CD11b in the stromal vascular fraction (SVF) of 
epididymal fat by flow cytometry and did not detect a difference (Figure 2.7 A). 
However, the process of isolating SVF involves centrifugation to separate 
adipocytes from the denser SVF cells. Therefore, lipid-laden macrophage foam 
cells, which are F4/80+ CD11b+, can be excluded from the SVF because they 
float to the top and are discarded as part of the adipocyte fraction. As such, we 
measured the expression of macrophage markers in whole adipose tissue by real 
time qRT-PCR and found that CD11b was significantly increased in the HFD fed 
CD40-/- mice (Figure 2.7 B). The macrophage population in the epididymal 
adipose tissue of CD40-/- mice tends to have higher expression of the 
proinflammatory integrin CD11c (Figure 2.7 B), suggesting an enhanced M1 
macrophage polarization in this fat depot (24). Consistently, macrophage 
infiltration was also increased in the epididymal adipose tissue of CD40-/- mice 
compared to their WT littermate controls (data not shown).  
 Since T cells can also infiltrate adipose tissue in HFD-induced obesity and 
contribute to metabolic dysfunction, we measured T cell content in the adipose 
tissue of CD40-/- mice.  We observed a 57% increase of CD3+CD90+ cells in the 
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epididymal SVF of HFD fed CD40-/- mice by flow cytometry (Figure 2.7 C). This 
increase was confirmed by measuring CD3 expression levels by qRT-PCR 
(Figure 2.7 D). We also analyzed the mRNA expression of inflammatory 
cytokines to confirm the elevated inflammation in the epididymal fat depot of 
CD40-/- mice. Tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ), 
two inflammatory cytokines expressed by activated macrophages and T cells, 
were both significantly increased (Figure 2.7 E). As increased obesity and 
inflammation are often associated with increased angiogenesis, we measured 
endothelial markers CD31 and von Willebrand factor (vWF) expression, which 
were both increased in the CD40-/- mice (Figure 2.7 F). These results suggest 
that CD40-/- mice have increased adipose tissue inflammation characterized by 
increased macrophage and T cell content and inflammatory cytokine expression. 
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Figure 2.7: CD40 protects against adipose tissue inflammation in obese 
mice. 
(A) After 24 weeks on HFD, the stromal vascular fraction (SVF) was isolated from 
epididymal adipose tissues of WT and CD40-/- mice and analyzed for CD11b and 
F4/80 expression by flow cytometry. Representative dot plots are shown on the 
left and summarized in bar graph on the right (n=8). (B) Gene expression of 
macrophage markers (F4/80, CD68, CD11b, CD11c and MGL-1) from whole 
epididymal adipose tissues (n=6). (C) SVF from epididymal adipose tissue of WT 
and CD40-/- mice was analyzed for CD3 and CD90 expression by flow cytometry. 
Representative dot plots are shown on the left and summarized in bar graph on 
the right (n=8). (D). Gene expression of CD3 from whole epididymal adipose 
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tissues (n=6).  (E) Gene expression of inflammatory genes (IFNγ, TNFα, IL-1β, 
IL-6, CD40, CD154 and SAA2) from whole epididymal adipose tissues (n=6). (F) 
Gene expression of CD31 and Von Willebrand factor (vWF) from whole 
epididymal adipose tissue (n=6). Data are presented as mean ± SEM. 
Statistically significant differences are indicated p < 0.05, **p<0.01 vs control. 
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Figure 2.7.2: CD40 protects against adipose tissue inflammation in obese 
mice. CD40-/- mice (n=4) on HFD for 10 weeks were compared to littermate 
controls (n=4). SVF was isolated from epididymal adipose tissue. (A) Tregs were 
defined as CD4+CD25+FoxP3+. (B) CD3+CD8+. (C) NK cells were defined as 
CD3-NK1.1+. (D) Macrophages were defined as CD11b+F4/80+.   
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CD40-/- mice have increased cytotoxic T cell content in the adipose tissue 
 Many different sub-populations constitute the normal repertoire of T cells 
in the adipose tissue of obese mice and humans. A previous study suggested 
that T cells contribute to the recruitment of adipose tissue macrophages and 
increased CD8+ effector T cells precede the accumulation of macrophages (30). 
Therefore, we investigated the proportion of these different T cells populations in 
the epididymal adipose tissue of CD40-/- and WT mice by flow cytometry. Of all 
CD3+CD90+ T cells, the percentage of CD4+ cells (T helper cells) was decreased 
by 29% and the percentage of CD8+ cells (cytotoxic T cell) in adipose tissue was 
about doubled in the CD40-/- mice  (Figure 2.8A, 2.8B and 2.8D). This increase in 
CD8+ cells was also observed when we used WT littermates as the control group 
(data not shown). The percentage of CD25+FoxP3+ regulatory T cells (Tregs), a 
subgroup of CD4+ T cells, was increased by 82% in the CD40-/- mice (Figure 2.8 
C), an increase that was also observed when WT littermates were used as the 
control group (data not shown). In summary, the absence of CD40 increased 
overall T cell abundance in adipose tissue and skewed the T cell population of 
adipose tissue towards increased CD8+ cells and decreased CD4+ cells (Figure 
2.8 D). 
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Figure 2.8. Deficiency of CD40 leads to increased CD8:CD4 ratio and 
increased Tregs in visceral adipose tissue of obese mice.  
(A) After 24 weeks on HFD, the SVF was isolated from epididymal adipose tissue 
of WT and CD40-/- mice and CD3+CD90+ cells were analyzed for CD4 and CD8a 
expression by flow cytometry. Representative dot plots are shown on the left and 
summarized in bar graph on the right (n=8). (B) Gene expression of CD4 and 
CD8 in the whole epididymal adipose tissue was measured by qRT-PCR (n=6). 
(C) SVF was isolated from epididymal adipose tissue of WT and CD40-/- mice 
and CD3+CD90+CD4+ cells were analyzed for the presence of FoxP3 and CD25 
by flow cytometry. Representative dot plots are shown on the left and 
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summarized in bar graph on the right (n=8). (D). Schematic pie chart showing the 
composition of total T cells defined as CD3+CD90+. Within this subset, Tregs are 
defined as FoxP3+CD4+CD25+. Data are presented as mean ± SEM. Statistical 
significances are indicated *p < 0.05. **p<0.01. ***p<0.001 vs control. 
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CD40-/- mice have increased eosinophil, B cell, NK/NKT cell infiltration in 
the adipose tissue 
 The roles of macrophages and T cells in adipose tissue inflammation are 
well described and recently literature has shown that other immune cell types are 
also present in obese adipose tissue (8, 31, 47). As such, we analyzed 
epididymal adipose tissue for the presence of eosinophils (Figure 2.9 A), B cells 
(Figure 2.9 B), NK and NKT cells (Figure 2.9C) and found that all were increased 
in CD40-/- mice fed HFD. NK cells were also increased in the epididymal adipose 
tissue of CD40-/- mice when WT littermates were used as the control group (3. 
2.7.2).  
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Figure 2.9: CD40 deficiency leads to increased eosinophil, B cell and 
NK/NKT cell recruitment into visceral adipose tissue in obese mice. 
After 24 weeks on HFD, the SVF was isolated from epididymal adipose tissue of 
WT and CD40-/- mice and analyzed for expression of (A) CD11b, siglec-f, (B) Gr-
1, CD19, (C) CD3 and NK1.1. Representative dot plots are shown on the left and 
summarized in bar graph on the right (n=8). Eosinophils were defined as 
CD11b+Siglec-f+. B cells were defined as Gr-1-CD19+. NK cells were defined as 
CD3-NK1.1+.  NKT cells were defined as CD3+NK1.1+. Data are presented as 
mean ± SEM. Statistical significances are indicated *p < 0.05. ***p<0.001 vs 
control. 
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Discussion 
Contrary to the generally accepted concept that disrupting the CD40-
CD40L signaling cascade alleviates inflammation [199, 204], we show here that 
CD40 deficiency in mice unexpectedly aggravates adipose tissue inflammation in 
obesity. This enhanced adipose inflammation in CD40 null mice includes 
increased recruitment of macrophages, CD8+ effector T cells and other immune 
cells including B cells, eosinophils, NK cells, NKT cells and Tregs (Figure 2.7, 
Figure 2.8 and Figure 2.9). Elevated immune cell infiltration into this tissue in 
CD40-/- mice creates a highly inflamed adipose depot characterized by increased 
levels of inflammatory cytokines (Figure 2.7E) and significantly higher basal 
lipolysis (Figure 2.6 D). The hydrolyzed FFAs from visceral adipose tissue are 
known to flow into the circulation via the portal vein and are then taken up by 
hepatocytes. This likely contributes to the development of the remarkable hepatic 
steatosis we observed in CD40-/- mice fed HFD (Figure 2.3 D), in the face of the 
decreased liver inflammation, expected when CD40 is deficient (Figure 2.5 C). 
With combined adipose tissue inflammation and steatotic liver, CD40-/- mice 
exhibit dramatic glucose intolerance and systemic insulin resistance (Figure 2.1 
D and Figure 2.2).  
We found that genetic deficiency of CD40 reduced food intake, which 
attenuated weight gain (Figure 2.1 B and 2.1 A), observations that were also 
noted in CD40L deficient animals [179]. These findings imply a common role of 
the CD40-CD40L axis in the regulation of energy homeostasis. Reduced food 
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intake and body weight gain often correlate with better insulin sensitivity. 
Surprisingly, we found aggravated insulin resistance in these CD40-/- mice as 
assessed by GTT, ITT and hyperinsulinemic-euglycemic clamp measurements 
(Figure 2.2 and 2.1 D). Of note, age matched C57BL/6J mice were used as 
wildtype controls for part of this study. These mice are known to be susceptible to 
diet-induced obesity and display glucose intolerance when fed HFD. The genetic 
locus underlying this phenotype was mapped to nicotinamide nucleotide 
transhydrogenase (Nnt) [208, 209]. C57BL/6J mice have a naturally occurring in-
frame five-exon deletion in Nnt that removes exons 7-11. Transgenic expression 
of the entire Nnt gene in C57BL/6J mice rescues their glucose intolerant 
phenotype [208]. Importantly, the CD40-/- mice used in this study, which are on 
the C57BL/6Ncr background, having intact Nnt gene, are more insulin resistant 
than the C57BL/6J controls, an effect that is in the opposite direction of that 
expected from the genetic background effect, if any exists, suggesting that CD40 
plays a critical role in regulating mouse whole body glucose hemostasis. 
The decreased steady-state GIR in clamp studies on CD40-/- mice could 
be caused by reduced efficiency of glucose disposal in tissues (muscle, adipose 
tissue, liver, heart and brain) as well as elevated hepatic glucose production. 
Indeed, reduced glucose uptake by brown adipose tissue is at least partly 
responsible for the overall decreased GIR in CD40-/- mice (Figure 2.1 E). Hepatic 
insulin resistance (Figure 2.4) in CD40-/- mice accounts for part of their overall 
systemic insulin resistance phenotype. We observed increased gene expression 
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of major regulators and enzymes (Figure 2.5 A and 2.5 C) in the 
gluconeogenesis pathway and increased hepatic glucose production in CD40-/- 
mice was confirmed by a pyruvate tolerance test (Figure 2.5 B). We were 
unsuccessful in detecting detect elevated hepatic glucose production in CD40-/- 
mice during our glucose clamp study (data not shown), but our study compared 
two groups of mice that were on a high fat diet for 16 weeks, therefore even the 
control mice were already highly insulin resistant. Thus, suppression of hepatic 
glucose output by insulin was already inhibited in the control mice making it 
difficult to detect a further significant inhibition for CD40-/- mice in the clamp 
study. 
The infiltration of activated macrophages into obese adipose tissue is 
correlated with adipose tissue dysfunction and systemic insulin resistance. CD8+ 
T cells also infiltrate into obese adipose tissue and their depletion improves 
systemic insulin sensitivity while adoptive transfer to CD8 null mice aggravates 
adipose tissue inflammation [112].  Despite reduced body weight, CD40 deficient 
animals on HFD exhibited increased adipose tissue inflammation and lipolysis 
(Figure 2.6 C & Figure 2.6 D). In the present study, we observed increased 
macrophages and T cells in the adipose tissue of CD40-/- mice with T cells 
increasingly biased towards CD8+ cells (Figure 2.7 and Figure 2.8). Importantly, it 
was reported that CD40 deficiency did not affect hematopoietic development or 
differentiation; therefore no systemic abnormality in the number and ratio of T 
and B cells was detected in these CD40 null mice [164].  Hence, the altered 
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population of immune cells in the adipose tissue of CD40-/- mice observed here is 
likely due to changes in the process of immune cell infiltration rather than defects 
in the development of lymphocytes. In addition to elevated macrophage and T 
cell infiltration into adipose tissue, we also noted a general increase of other 
immune cells, including B cells, eosinophils, NK cells and NKT cells (Figure 2.9).  
Interestingly, Tregs and eosinophils are typically correlated with decreased 
inflammation in obesity [110, 123]. We believe their presence in the inflamed 
CD40-/- adipose tissue may play an important compensatory role to neutralize the 
deleterious effect from the activated macrophage and CD8+ effector T cells. 
Previous studies on CD40L-/- mice indicated that CD40L deficiency attenuates 
HFD-induced adipose tissue inflammation [177, 179], which is opposite to what 
we observed here in CD40-/- mice.  However, since CD40L can signal through a 
non-CD40 pathway [160], differences between CD40-/- and CD40L-/- mouse 
models are not surprising.   
The surprising elevation in the adipose tissue inflammation in CD40-/- mice 
was accompanied by an expected decrease in hepatic inflammation due to the 
CD40 deficiency (Figure 2.5 C). The remarkably elevated hepatic steatosis in 
CD40-/- mice fed a HFD is consistent with two reports on CD40L-/- mice [177, 178] 
but inconsistent with another [179]. The discrepancy among different studies on 
CD40L deficient mice could be due to different sources of HFD used in each 
study. In concert with the morphological changes we observed, the more 
steatotic livers of CD40-/- mice show significantly higher expression of hepatic 
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CIDEA and FSP27, two lipid droplet proteins that are not normally expressed in 
lean livers (Figure 2.3F).   
Studies in rodents and humans have revealed that the accumulation of TG 
observed in hepatic steatosis is mainly due to the increased availability of free 
fatty acids (FFAs) arising from the visceral adipose tissue through unabated 
lipolysis as well as increased hepatic lipogenesis. These two pathways appear to 
account for more than 80% of the fat storage in steatotic livers [191]. In our 
study, the increased hepatic steatosis in CD40-/- mice may be in part a result of 
fatty acid overflow from adipose tissue lipolysis (Figure 2.6 D). Chronic exposure 
of tissues to elevated FFAs is known to induce impaired responsiveness of Akt to 
insulin and decreased insulin signaling [210]. Indeed, we observed impaired 
insulin-mediated phosphorylation of Akt (Ser473) in the livers of CD40-/- mice 
upon acute insulin treatment (Figure 2.4). 
How can the deficiency of a proinflammatory receptor protein that normally 
activates adaptive immunity paradoxically cause elevated inflammation in the 
adipose tissue of mice? We found increased immune cell infiltration in the 
adipose tissue of CD40-/- mice but decreased inflammation in the liver, 
suggesting that the phenotype observed is tissue specific and not due to a global 
defect of the immune system. One possible mechanism could involve endothelial 
cells in adipose tissue. Endothelial cells control leukocyte entry into tissues from 
the vasculature through the expression of adhesion molecules involved in 
leukocyte rolling and extravasation. CD40 is present on both epithelial and 
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endothelial cells and different vascular beds express various levels of CD40 
[211]. Previous studies demonstrated that the CD40-CD40L dyad affects 
endothelial cell function and migration during angiogenesis [212, 213]. In our 
studies presented here, increased expression of endothelial cell markers von 
Willebrand factor and CD31 in the adipose tissue of CD40-/- mice (Figure 2.7 F) 
suggests an increased presence of endothelial cells. In contrast, CD40 
expression in the vascular beds of the liver is undetectable [211]. Future studies 
will be needed to test whether adipose endothelial cell disruption of CD40 might 
lead to the phenotype we observed in CD40 null mice. 
In summary, results from the present study indicate that CD40 deficiency 
exacerbates inflammation in visceral adipose tissue, further promoting the 
negative metabolic manifestations in obesity, such as insulin resistance and 
hepatic steatosis. This hepatic steatosis is not associated with localized 
inflammation. We thus have identified a unique mouse model whereby an 
apparent primary inflammation and disruption of adipose function leads to 
hepatic steatosis without liver inflammation. These findings reveal the co-
stimulatory signaling CD40-CD40L dyad as an important feature controlling 
adipose tissue inflammation and its connection to metabolic disease and glucose 
intolerance. 
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CHAPTER III: Similarity of Mouse Perivascular and Brown Adipose Tissue 
and their Resistance to Diet Induced Inflammation 
 
Disclaimer: Experiments were performed in collaboration with the following 
individuals: 
Figures 3.1, 3.2 and 3.3 were performed by Timothy Fitzgibbons. Figure 3.4 
which was done by Greg Hendricks; Figures 3.6 and 3.7 were done by the 
Morphology Core and the microarray hybridizations by the Genomics Core of the 
Diabetes and Endocrine Research Center (DK-32520). Jeurg Straubhaar 
uploaded the microarray data to MACE and performed detailed statistical 
analyses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is in the format published: Timothy P. Fitzgibbons, Sophia Kogan, 
Myriam Aouadi, Greg M. Hendricks, Jeurg Straubhaar, and Michael P. Czech. 
Similarity of mouse perivascular and brown adipose tissues and their resistance 
to diet-induced inflammation. Am J Physiol Heart Circ Physiol 301: H1425-
H1437, 2011. 
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Abstract 
Thoracic perivascular adipose tissue (PVAT) is a unique adipose depot that likely 
influences vascular function and susceptibility to pathogenesis in obesity and 
metabolic syndrome. Surprisingly, PVAT has been reported to share 
characteristics of both brown and white adipose, but a detailed direct comparison 
to interscapular brown adipose tissue (BAT) has not been performed. Here we 
show by full genome DNA microarray analysis that global gene expression 
profiles of PVAT are virtually identical to BAT, with equally high expression of 
Ucp-1, Cidea and other genes known to be uniquely or very highly expressed in 
BAT. PVAT and BAT also displayed nearly identical phenotypes upon 
immunohistochemical analysis, and electron microscopy confirmed that PVAT 
contained multilocular lipid droplets and abundant mitochondria. Compared to 
white adipose tissue (WAT), PVAT and BAT from C57BL6/J mice fed a high fat 
diet for 13 weeks had markedly lower expression of immune cell-enriched 
mRNAs, suggesting resistance to obesity induced inflammation.  Indeed, staining 
of BAT and PVAT for  macrophage markers (F4/80, CD68) in obese mice 
showed virtually no macrophage infiltration, and FACS analysis of BAT confirmed 
the presence of very few CD11b+/CD11c+ macrophages in BAT (1.0%) in 
comparison to WAT (31%).   In summary, murine PVAT from the thoracic aorta is 
virtually identical to interscapular BAT, is resistant to diet induced macrophage 
infiltration, and thus may play an important role in protecting the vascular bed 
from inflammatory stress. 
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Introduction 
The burgeoning prevalence of obesity and diabetes throughout the world 
threatens to accelerate the incidence of associated cardiovascular diseases, 
including coronary artery disease, hypertension, and congestive heart failure.  
Although the mechanism by which obesity causes vascular disease is not fully 
understood, insulin resistance and the  metabolic syndrome are thought to play a 
major role[2, 8, 186, 214, 215].  In human obesity as well as mouse models of 
obesity, enlarged adipocytes in visceral adipose tissue become insulin resistant  
and fail to effectively store excess triglyceride through decreased capacity for 
lipogenesis and increased lipolysis [2, 8, 214, 216, 217].   These changes in 
adipose function lead to infiltration of immune cells, which are thought to cause 
chronic low grade inflammation in obese subjects with the metabolic syndrome 
[8, 218].  Lipid overload in the face of decreased capacity of adipocytes to store 
triglycerides leads to ectopic lipid deposition in liver and muscle resulting in 
systemic insulin resistance [8, 80].  Prolonged obesity with these associated 
disorders is thought to be the major cause of beta cell failure and type 2 diabetes 
in humans. 
It is now well established that expansion of visceral adipose tissue (VAT), 
rather than subcutaneous adipose tissue (SAT), confers a high risk for the 
metabolic syndrome and incident cardiovascular disease [2, 186, 219].  
Hypotheses for this observation include: increased expression of 
angiotensinogen and complement, a greater rate of monocyte infiltration, and 
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increased IL6 secretion in VAT compared to SAT [220].  It has also been 
postulated that the elevated rates of lipolysis in VAT compared to SAT render the 
former less able to sequester triglycerides away from liver and muscle [221].   
These and other important differences between VAT and SAT have stimulated 
interest in the discovery of additional adipose depots, which might have similar or 
increasingly pathologic functions in obesity.  One such adipose depot is 
perivascular adipose tissue (PVAT), which was recently proposed to be a 
potential link between diabetes and cardiovascular disease[222-226].  The 
outermost connective tissue or adventitia surrounding an artery, including PVAT, 
may be prone to the same inflammation as VAT, and the idea that vascular 
disease could be impacted and perhaps promoted by factors in the adventitia has 
long-standing support [227-230].  
  Initial studies of PVAT from human coronary arteries surprisingly detected 
expression of some BAT-specific genes (PRDM16, UCP-1, CPT1B) to a degree 
that appeared intermediate to white and brown adipose tissues [222].  These 
studies suggested PVAT might be an example of the recently described “brite” 
adipose tissue--white adipose that retains many of its usual characteristics but 
also displays some expression of BAT genes, including Ucp-1 [231]. 
Interestingly, in rodents, PVAT surrounding the abdominal aorta displays 
characteristics of white adipose tissue, whereas PVAT surrounding the thoracic 
aorta appears quite different, and is known to express some BAT genes [26, 
225].  Although thoracic PVAT showed similarities to BAT in morphology and 
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expressed Ucp-1, a direct detailed genomic comparison to true interscapular 
BAT has not yet been made [26, 225]. The extent to which thoracic PVAT in mice 
is more similar to human coronary PVAT, which displays only partial similarity to 
BAT, or to true interscapular BAT is an important question since mice are 
frequently used as models of human cardiovascular disease.  
We addressed this question by directly comparing genome wide 
expression of  thoracic PVAT to brown and white adipose depots from mice fed a 
normal or high fat diet for 13 weeks.  Remarkably, PVAT and BAT had virtually 
identical gene expression profiles. Furthermore, in comparison to the infiltration 
of macrophages into VAT of obese mice and the increased expression of 
macrophage enriched genes in this tissue, thoracic PVAT and BAT were 
strikingly resistant to inflammation induced by high fat feeding, as shown by 
microarray, immunohistochemistry, and FACS analysis.  We conclude that PVAT 
surrounding the murine thoracic aorta is virtually identical to interscapular BAT, 
and like BAT is resistant to inflammation under HFD conditions.  
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Materials and Methods 
Animal Studies 
Male C57BL6/J mice were purchased from the Jackson Laboratory (Bar Harbor, 
ME).  All animals were fed normal chow until 8 weeks of age.  Animals were then 
divided into two groups; one fed normal chow and one fed high fat diet (45 kcal% 
fat, D12451 Research Diets) for 13 or 20 weeks. Animals were fed ad libitum with 
free access to water and housed in the UMASS Animal Medicine facility with a 
12:12 light dark cycle.  Animals were weighed weekly for the duration of the diet 
study.   Intraperitoneal (i.p.) glucose tolerance testing (GTT) was performed as 
previously described [232].  Area under the curve for the GTT was calculated 
using the trapezoidal method [233].  At the completion of the high fat diet,  mice 
were fasted for 6 hours and  then euthanized with CO2 inhalation and bilateral 
pneumothorax.  SAT (inguinal), VAT (epididymal) and BAT(interscapular)  were 
harvested and snap frozen in liquid nitrogen.    Blood was drawn via cardiac 
puncture into heparin coated tubes and the circulatory system was perfused with 
ice cold PBS.  Thoracic PVAT directly adjacent to the lesser curvature of the 
aortic arch was then harvested and snap frozen in liquid nitrogen.  All 
experiments were performed in accordance with protocols approved by the 
Animal Care and Use Committee at UMASS Medical School. 
   
 
 
99
Insulin levels 
Blood was collected via cardiac puncture at the time of euthanasia into heparin 
coated microcentrifuge tubes and centrifuged at 3000 x g for 15 minutes.  Serum 
was then decanted and stored at -80 °C.  Fasting insulin levels were measured in 
duplicate with 10 µl of serum using a Rat/Mouse Insulin ELISA (Millipore, St. 
Charles, MO) according to the manufacturers’ instructions. 
 
Quantitative PCR 
Adipose tissue was isolated as previously described, snap frozen in liquid 
nitrogen and stored at -80°C.  Tissues were homogenized and total RNA was 
isolated with RNA Mini Lipid kits (Qiagen, Valencia, CA).  250 ng total RNA was 
reverse transcribed with the Bio-Rad iScript cDNA Synthesis Kit (Bio-Rad, 
Hercules, CA).  cDNA was diluted 1:5 and 2.5 µl was used in a 12.5 µl reaction 
volume; each reaction was performed in duplicate.  Real time qPCR was 
performed with a Bio-Rad C1000 Thermal Cycler and SYBR Green Master Mix 
(Bio-Rad, Hercules, CA) using the following cycle parameters: 95.0° C for 3 min, 
95.0° for 0:10 min, 60.0° C for 0:15 min, 72.0° C for 0:30 min for 40 cycles.  
Expression was normalized to the reference gene 36b4 and expressed as 
relative to expression in SAT of normal diet mice using the 2 –ΔΔct method [207].  
Melt curve analysis and agarose gel electrophoresis was performed to determine 
the specificity of the PCR reaction products.  Primer sequences were: Ucp-1 for  
AGGCTTCCAGTACCATTAGGT, Ucp-1 rev CTGAGTGAGGCAAAGCTGATTT,  
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Acrp30  for TGTTCCTCTTAATCCTGCCA and Acrp30 rev 
CCAACCTGCACAAGTTCCCTT, 36b4 for TCCAGGCTTTGGGCATCA, 36b4 rev 
CTTTATCAGCTGCACATCACTCAGA, Cidea for 
ATCACAACTGGCCTGGTTACG, Cidea rev TACTACCCGGTGTCCATTTCT, 
PPARγ2 for ATGGGTGAAACTCTGGGAG, and PPARγ2 rev 
GTGGTCTTCCATCACGGAGA. 
 
Microarray Analysis 
RNA was isolated from SAT, VAT, BAT, and PVAT as previously described.  
RNA concentrations were determined using a Nanodrop 2000 
Spectrophotometer (Thermo Fisher, Willmington, DE).  The RNA quality was 
assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, 
CA).  Only samples with a RNA Integrity Number >7.5 and normal 18 and 28s 
fractions on microfluidic electrophoresis were used.  RNA from two mice per 
tissue and diet was pooled for a total of 250 ng total RNA template for cDNA 
synthesis and in vitro transcription using the Ambion WT Expression kit (Ambion, 
Carlsbad, CA).  Second strand cDNA was then labeled with the Affymetrix WT 
Terminal Labeling kit and samples were hybridized to Affymetrix Mouse Gene 1.0 
ST arrays (Affymetrix, Santa Clara, CA).  Gene chip expression array analysis for 
individual genes was performed as previously described [233], filtering for p 
<0.05 and a fold change of >2.  Three biological replicate hybridizations per 
tissue and diet were performed, for a total of 24 hybridizations.      Robust multi-
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array average (RMA) was adopted in the UMASS Microarray Computational 
Environment (MACE) to preprocess raw oligonucleotide microarray data. The 
algorithm was implemented as a function of the R package Affy [234], which is 
part of the Bioconductor project [235] using the statistical computing language R 
(R Foundation for Statistical Computing, Vienna, Austria).  All statistical 
calculations are performed using the R statistical computing environment and 
results are stored in a relational database.  The preprocessed data are stored as 
base 2 log transformed real signal numbers and are used for fold-change 
calculations and statistical tests and to determine summary statistics. Mean 
signal values and standard deviations are computed for each gene across 
triplicate experiments and stored in the database. The fold change of expression 
of a gene in two experiments is the ratio of mean signal values from these 
experiments and is always a number greater than one. If the ratio is less than 
one, the negative value of the inverse ratio is stored as fold change. All down 
regulated genes therefore have a negative fold change value, up regulated 
genes have a positive fold change. In both cases this value is greater or equal 
than one. 
To determine differential expression of genes in two hybridization 
experiments MACE internally conducts a Student’s t-test with the expression 
signal values of the two hybridizations for all genes in the set. The t-test value 
and test p-value are stored in MACE and can be queried through the MACE user 
interface. The p-values stored and displayed as a result of a query are not 
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adjusted for multiple testing.  The data discussed in this publication have been 
deposited in NCBI’s Gene Expression Omnibus [236] and are accessible through 
GEO Series accession number GSE28440 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE28440).  
 
Histology and Immunohistochemistry 
Adipose tissue samples (n=3 per group) from normal and high fat diet animals 
were fixed in 4% formalin for immunohistochemistry.  Briefly, samples were 
embedded in paraffin, sectioned, and stained with a rat anti-mouse F4/80 (ABd 
Serotec, Raleigh, NC)(1:50 dilution) or rat anti-mouse CD68 primary antibody 
(ABd Serotec, Raleigh, NC)(1:40 dilution).  Staining was visualized with a HRP 
linked rabbit anti-rat secondary anti-body.  Staining with the secondary antibody 
alone was performed as a negative control.  Images were taken with a Zeiss 
Microscope and PixeLINK SE Software. 
 
Transmission electron microsopy of adipose tissue samples 
Adipose tissue samples were fixed in 2.5% glutaraldehyde in PBS (pH 
7.2).   Tissue samples were dissected into 1 mm blocks and the tissues washed 
three times and left overnight in fresh buffer.  The next morning the samples 
were post-fixed for 1 hr in 1% osmium tetroxide.  The fixed adipose tissue 
samples were then washed again in the PBS and dehydrated through a graded 
series of ethanol to 100% and transferred through two changes of propylene 
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oxide and finally into a 50:50  (v/v)mixture of  propylene oxide: epoxy resin 
(SPON 812/Araldite 502 ) and left overnight to infiltrate.  The following morning 
the adipose tissue samples were processed through two changes of fresh epoxy 
resin and embedded, allowing the blocks to polymerize 48 hrs at 70°C.  
Blocks of tissue were then selected, cut out and attached to blank epoxy stubs 
with a drop of Super Glue.  Ultrathin sections were cut on a Reichart-Jung 
ultramicrotome using a diamond knife.  The sections  (64 nm thick) were 
collected and mounted on copper support grids and contrasted with lead citrate 
and uranyl acetate and examined on a Philips CM 10 transmission electron 
microscope at 80 Kv accelerating voltage.   
 
FACS Analysis 
Mice were euthanized and BAT and VAT was removed and treated with 4 mg/mL 
and 2 mg/mL collagenase respectively in 4% BSA in PBS at pH=7.4 for 1 hour. 
Samples were filtered through 200µM and 30 µM spectra mesh sequentially and 
stained with CD31 (BD Biosciences, Franklin Lakes, NJ; 1:1000 dilution), CD11b 
(BD Biosciences, Franklin Lakes, NJ; 1:200 dilution) and CD11c (BD 
Biosciences, Franklin Lakes, NJ; 1:200 dilution) according to the manufacturer’s 
instructions. Samples were run on a BD LSRII flow cytometer (BD Biosciences, 
Franklin Lakes, NJ) and analyzed in Flow Jo, gating for CD31 negative cells.  
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Statistical Analysis 
All values are shown as mean ± SEM.  For experiments other than the 
microarray analyses, the Student’s t test for two tailed distributions with equal 
variances was used for comparison between 2 groups; for comparisons greater 
of ≥ 3 groups, two way ANOVA followed by the Bonferroni correction was used.   
Differences less than p ≤ 0.05 were considered significant.  Data was entered 
into Microsoft Excel and statistical analyses were performed with Graph Pad 
Prism 5. 
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RESULTS 
Cidea and Ucp-1 are highly expressed in BAT and PVAT independent of 
obesity. 
  HFD mice (n=12) gained more weight than ND mice (n=12) beginning at 3 
weeks and remained significantly more obese until the end of the study (30.9 ± 
0.75 vs. 42.08 ± 0.78 gms p<0.001).  At the end of 13 weeks, HFD mice were 
more glucose intolerant as shown by an elevated fasting blood glucose 
concentration (136.4 ± 1.22 vs. 185.8 ± 21.4 mg/dL p<0.02), elevated fasting 
insulin levels (2.1 ± 0.64 vs. 5.4 ± 1.03 ng/mL p<0.02), and increased area under 
the curve for the IPGTT ((min*mg/dL) =29352 ± 753 vs. 38983 ± 1928 p<0.01). 
  Analysis of mRNA from adipose tissue samples by qPCR showed that 
Cidea and Ucp-1 were highly expressed in PVAT and BAT compared to SAT.  
Remarkably, the relative expression between these two depots was similar for 
both genes (Figure 3.1 A, B).  Interestingly, Cidea expression was reduced >50% 
by HFD in both PVAT and BAT; this effect was not observed for Ucp-1 (Figure 
3.1 A, B).  With respect to other markers of adipose differentiation, PPARγ2 
expression was slightly greater in VAT, PVAT, and BAT than SAT and 
significantly reduced by HFD in these depots (Figure 3.1 D).  Adiponectin 
(Acrp30) expression was significantly greater in VAT and decreased with HFD 
(Figure 3.1 C); expression of this gene was similar in all other depots.  Therefore, 
PVAT expresses Cidea and Ucp-1 to an equivalent degree as BAT, suggesting 
that it may be more similar to BAT than “brite” adipose tissue.  Furthermore, it is 
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responsive to HFD and not different from other adipose depots with respect to 
makers of adipose differentiation, such as PPARγ2 and Acrp30.   
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Figure 3.1: Cidea and Ucp-1 are highly expressed in interscapular brown 
adipose tissue (BAT) and perivascular adipose from the aortic arch (PVAT) 
independently of obesity. A, B, C, and D: Cidea, Ucp-1, Acrp30, and Pparγ2 
expression in normal diet (ND) and high-fat diet (HFD) mice. Quantitative PCR 
was performed on total RNA isolated from inguinal (SAT), epididymal (VAT), 
BAT, and PVAT. Expression levels were calculated with the 2−ΔΔCt method 
using 36b4 as the reference gene and normalized to expression in SAT from ND 
conditions. Ucp-1 expression is shown in log10 scale. AU, arbitrary units. ND: n = 
12 white; HFD: n = 12, black. Results are means ± SE. ***P < 0.001 vs. SAT ND; 
#P < 0.05. ND vs. HFD of the same fat depot using two-way ANOVA and the 
Bonferonni correction; P < 0.05 vs. SAT ND. 
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Mouse Thoracic PVAT is morphologically similar to BAT. 
  In order to test the hypothesis that thoracic PVAT is virtually identical to 
interscapular BAT, we performed microscopic analysis of these adipose depots.  
As judged by light microscopy on hematoxylin and eosin stained sections of 
PVAT and BAT under ND and HFD conditions, PVAT appeared very similar to 
BAT, with round nuclei, and small, multilocular lipid droplets (Figure 3.2 G). The 
majority of PVAT surrounding the thoracic aorta had the appearance of BAT, with 
small areas of adipose tissue resembling WAT (Figure 3.2 G).  BAT lipid droplet 
architecture was obviously distorted by 13 weeks of HFD, with enlargement and 
coalescence of lipid droplets (Fig. 3.2 F). Surprisingly, this effect was not 
apparent in PVAT, although it did occur with a longer duration of HFD (Figure 3.6 
H). 
  Transmission electron microscopy confirmed the BAT phenotype of 
thoracic PVAT, and detected some interesting differences compared to 
interscapular BAT (Figure 3.3).  Both PVAT and BAT from mice fed ND were 
densely packed with mitochondria and had mulitilocular lipid droplets which were 
darkly stained with osmium tetroxide (Figure 3.3 A, C). Interestingly, lipid droplets 
in BAT tended to lose their avidity for osmium when obtained from mice after 
high fat feeding, mostly appearing white (Fig. 3B). This effect was not observed 
in PVAT (Figure 3.3 D).  High fat feeding resulted in significant mitochondrial 
swelling and unfolding of cristae in PVAT (Figure 3.3 D), which was not apparent 
in BAT at this time point, but visible after a longer duration of HFD (Data not 
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shown).  These observations correlated with changes in gene expression.  For 
example, Fads1 was significantly downregulated (-1.82) in BAT compared to 
PVAT in HFD conditions.  Likewise, a search for alterations in the expression of 
mitochondrial genes revealed that expression of the proapoptotic gene Bid and 
mitochondrial solute carrier genes Slc25a35 and Slc25a37 were upregulated in 
PVAT compared to BAT in HFD conditions; a third member of this latter gene 
family, the calcium binding carrier protein Aralar1(Slc25a12), was significantly 
upregulated in BAT compared to PVAT (2.58 FC, p=0.002, Supplemental Table 
S4).  Therefore, thoracic PVAT and BAT appear virtually identical upon analysis 
by both light and electron microscopy, with the exception of subtle differences in 
lipid droplet and mitochondrial morphology, which correlate with changes in gene 
expression.   
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Figure 3.2: PVAT appears morphologically similar to BAT. Fat was harvested 
from SAT (A and B), VAT (C and D), interscapular BAT (E and F), and PVAT (G–
J) from the lesser curvature of the aortic arch from ND and HFD fed mice and 
then fixed in formalin. Tissues were stained with hematoxylin and eosin and 
visualized at ×25. Images G and H are low magnification images (×6.3) of I and 
J. Ao, aortic lumen. 
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Figure 3.3: Transmission electron microscopy reveals many similarities 
between PVAT and BAT. Sections of brown (A and B) and perivascular adipose 
(Cand D) were taken and stained with osmium tetroxide. In ND conditions, brown 
(A) and perivascular adipose (C) appear very similar with mulitilocular lipid 
droplets and abundant mitochondria. Two prominent changes were noted in high-
fat feeding conditions; lipid droplets in BAT, but not PVAT, lose their avidity for 
osmium textroxide (B), and mitochondria become swollen with unfolded cristae 
(D); the latter effect was more prominent in perivascular adipose but also 
observed in brown adipose after a longer duration of HFD. LD, lipid droplet; M, 
mitochondria; EC, endothelial cell; RBC, red blood cell. Magnification: ×7900; 
scale bar = 2 µm. 
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Microarray analysis confirms PVAT has a characteristic brown adipose 
gene expression signature. 
  To validate and expand the above findings, DNA microarrays were used to 
contrast global differences in gene expression between adipose depots from 
mice under control and high fat feeding conditions.  Total RNA was hybridized to 
Affymetrix Mouse Gene 1.0 ST chips, each of which contains probes targeting 
28,853 genes.  Analysis of the full genome set of gene expression differences 
among the four adipose depots showed high similarity of PVAT to BAT, and a 
much greater divergence of gene expression when compared to white adipose 
depots (SAT,VAT)(Figure 3.4, Table 3.1).  When comparing PVAT to BAT in 
normal diet conditions, only 228 genes demonstrated significantly different 
expression (Figure 3.4).  With regard to the specific genes, which were 
differentially expressed, in comparison to BAT, PVAT had greater expression of 
immunoglobulin genes (IgK, Igh-6), complement (Cfh, C7), and mast cell specific 
genes (Mcpt4)(not shown).  In contrast, the vast majority of genes whose 
expression was greater in BAT than PVAT were related to skeletal muscle 
differentiation and function.   Interestingly, additional genes expressed to a 
greater extent in BAT than PVAT were highlighted by the mesodermal 
developmental genes Tbx15 (3.8 fold), Myf6 (3.2 fold), and Zic1 (2.1 fold)(not 
shown). 
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Next, we refined this analysis by comparing gene expression differences 
in PVAT relative to BAT and SAT from mice fed ND with respect to selected 
specific gene categories (Table 3.1).    Strikingly, there were no significant 
differences between PVAT and BAT in levels of expression of any genes known 
to be highly expressed in brown adipocytes (Table 3.1).  Nor were there any 
differences between PVAT and BAT under ND conditions in the expression of the 
majority of specific genes examined, with the exception of  Fads1 (Table 3.1).  In 
contrast to these virtually identical gene expression profiles between PVAT and 
BAT, highly significant decreases in expression were displayed by brown 
adipocyte enriched genes in SAT and VAT compared to PVAT (Table 3.1).  As 
expected, expression of white adipose enriched genes was significantly greater 
in SAT and VAT compared to PVAT (Table 3.1).  In other gene categories, 
expression of the adipokines Lep, Retn, Rbp4, and Adipoq was higher in SAT 
and VAT, whereas the receptors for Adipoq (Adipor1/Adipor2) were more highly 
expressed in PVAT (Table 3.1).  In regards to lipid metabolism genes, those 
involved in synthesis or storage (Fads1, Fads3, Cidec) were expressed to a 
greater extent in SAT and VAT, whereas those functioning in lipid oxidation 
(Gpam, Acss1, Acsl5) were more highly expressed in PVAT and BAT (Table 3.1).  
Surprisingly, expression of immune cell enriched genes, such as chemokines 
(Ccl5, Ccl8), T cell receptors (Cd3g, Cd3d), and macrophage markers (Cd68, 
Emr1) was significantly greater in SAT and VAT compared to PVAT and BAT 
even under ND conditions (Table 3.1).  Given this dramatic difference in 
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expression of immune cell genes in white compared to brown adipose depots, we 
compared the effects of high fat feeding on changes in expression of immune cell 
enriched genes in the four adipose depots. 
Shown in Table 3.2 are the fold changes in expression for a series of 
selected immune cell enriched genes when comparing ND to HFD conditions in 
PVAT, BAT, SAT and VAT depots.  VAT demonstrated the greatest fold increase  
in expression of immune cell genes after high fat feeding (Table 3.2).  Although 
the other depots exhibited some trends for changes in gene expression between 
ND and HFD fed mice, none of them met statistical significance (Table 3.2).    
Taken together, the data in Figure 3.4 and Tables 3.1 and 3.2 reveal a 
remarkably similar global gene expression profile between PVAT and BAT. 
These two adipose depots show no significant differences in expression in the 
majority of genes previously shown to be enriched in brown adipocytes, white 
adipocytes or immune cells.  In addition, the data in Table 3.2 is particularly 
revealing in that the levels of expression of immune cell genes, as reflected by 
their probe set signals, is uniformly higher in both SAT and VAT compared to 
PVAT and BAT in both ND and HFD conditions. These data imply that the PVAT 
and BAT depots are relatively resistant to inflammation induced by high fat 
feeding compared to WAT depots.   
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Figure 3.4: Microarray analysis reveals that PVAT is more similar to BAT 
than SAT or VAT. Microarray Computational Environment (MACE) database 
was queried in ND and HFD conditions for genes with a >2.0 fold change in 
expression at P < 0.05 level of significance between adipose depots. In ND 
conditions, PVAT was very similar to BAT, with differential expression of only 228 
genes (0.79% of genes); in contrast, expression of 1,229 genes was differentially 
regulated when comparing PVAT and SAT (4.2% of genes). After high-fat 
feeding, PVAT became more similar to white adipose, as the number of genes 
differentially regulated between PVAT and SAT was reduced to 855 (2.9% of 
genes). White arrows, upregulated; black arrows, downregulated. 
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 PVAT vs. SAT PVAT vs. VAT PVAT vs. BAT 
Symbol FC P value FC P value FC P value  
Most Highly Enriched Genes 
Ucp1 21.6 <0.001 31.2 <0.001 1.0 NS 
Elovl3 19.3 <0.001 29.3 <0.001 1.1 NS 
Slc27a2 17.9 <0.001 17.2 <0.001 1.4 NS 
Cox7a1 16.1 <0.001 23.1 <0.001 1.0 NS 
Cpt1b 14.5 <0.001 24.7 <0.001 1.0 NS 
Kng2 14.0 <0.001 12.4 <0.001 1.2 NS 
Acot11 12.6 <0.001 15.8 <0.001 1.0 NS 
Cidea 12.6 <0.001 31.8 <0.001 1.1 NS 
Brown adipose-enriched genes 
Ucp1 21.6 <0.001 31.2 <0.001 1.0 NS 
Elovl3 19.3 <0.01 29.2 <0.001 1.1 NS 
Slc27a2 17.8 <0.001 17.1 <0.001 1.4 NS 
Cox7a1 16.1 <0.001 23.0 <0.001 1.0 NS 
Cpt1b 14.5 <0.001 24.7 <0.001 1.1 NS 
Cidea 12.6 <0.001 31.7 <0.001 1.1 NS 
Dio2 8.0 <0.001 9.9 <0.001 -1.1 NS 
Prdm16 1.8 <0.001 2.41 <0.001 1.0 NS 
White adipose-enriched genes 
Hoxc8 -9.7 <0.001 -17.7 <0.001 2.1 NS 
Apol7c -8.2 <0.01 -1.6 NS 1.2 NS 
Dapl1 -6.3 <0.01 -2.0 NS 1.8 NS 
Nnat -6.1 <0.01 -6.9 <0.01 1.1 NS 
Sncg -4.2 <0.01 -5.5 <0.001 1.0 NS 
Stap1 -4.7 <0.05 -1.4 NS 2.9 NS 
Grap2 -3.9 <0.01 -1.4 NS 1.5 NS 
Mest -3.8 <0.01 -14.2 <0.001 1.0 NS 
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Table 3.1: Depot-specific expression of select gene categories in normal 
diet conditions. The eight most highly up-regulated genes in PVAT vs. SAT in 
normal diet conditions were ranked in descending order. Expression levels of the 
same genes in PVAT vs. VAT and PVAT vs. BAT in normal diet conditions were 
then queried, and are included in the last two columns for comparison. 
Expression of genes from select categories was also queried in normal diet 
conditions, and ranked in descending order according to expression in SAT. 
Genes with significantly increased expression in PVAT are in bold and genes 
with significantly decreased expression in PVAT are italicized. NS = not-
significant.  
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Il7r -5.7 <0.01 -1.3 NS 2.4 NS 
Ccl5 -5.6 <0.05 -1.3 NS 1.6 NS 
Cd3g -5.0 <0.01 -1.7 NS 2.3 NS
Ccl8 -4.1 <0.01 1.0 NS -1.3 NS
Ccr7 -4.0 <0.05 -1.3 NS 1.4 NS
Cd3d -3.1 <0.05 -1.2 NS -1.1 NS
Cd68 -2.3 <0.05 -1.9 <0.05 -1.3 NS
Emr1 -2.1 <0.05 -2.3 <0.01 -1.3 NS
Fatty acid biosynthesis and metabolism 
Fads3 -2.5 <0.01 -4.5 <0.001 -1.1 NS
Fads1 1.5 NS -1.8 <0.01 -1.7 <0.05 
Cidec -1.1 <0.05 -1.6 <0.01 -1.3 NS
Scd1 -1.0 NS -1.0 NS 1.0 NS
Fasn -1.5 NS -1.5 NS 1.0 NS
Gpam 2.6 <0.001 1.4 <0.01 1.0 NS
Acss1 3.2 <0.001 4.9 <0.001 1.1 NS
Acsl5 3.7 <0.001 4.2 <0.001 1.1 NS
Adipokine and related effector genes 
Lep -2.7 <0.05 -4.6 <0.01 -1.3 NS
Retn -1.8 <0.001 -2.1 <0.001 -1.8 NS 
IL6st -1.4 <0.001 -1.4 <0.01 -1.2 NS
Rbp4 -1.4 <0.05 -2.3 <0.001 -1.0 NS
Adipoq -1.3 <0.05 -1.6 <0.01 -1.1 NS
Tnfaip6 -1.3 <0.05 -1.2 <0.05 -1.0 NS
Adipor1 1.3 <0.01 1.1 <0.05 -1.0 NS
Adipor2 1.4 <0.05 -1.1 NS 1.0 NS
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Table 3.2: Comparative expression of immune cell enriched genes in VAT, 
SAT, PVAT and BAT in normal and high fat diet conditions.   
 
 
 
 
 
 
 
 
 
 
TAB E 2.2   Compar tive expression of immune cell enriched       
          
                
               
                
              
 
 SAT VAT PVAT BAT 
Symbol ND HFD FC P ND HFD FC P ND HFD FC P ND HFD FC P 
Il7r 2038 1299 -1.5 NS 268 2779 10.4 <0.001 178 350 1.9 NS 62 164 2.6 NS 
Tlr13 564 531 -1.1 NS 397 2404 6.0 <0.001 133 343 2.6 NS 151 243 1.6 NS 
Il1rn 444 499 1.1 NS 367 1923 5.2 <0.001 220 403 1.8 NS 208 269 1.2 NS 
Cd84 665 574 -1.2 NS 426 2079 4.9 <0.001 128 281 2.2 NS 92 171 1.9 NS 
Mpeg1 1527 1292 -1.2 NS 713 3311 4.6 <0.001 240 555 2.3 NS 233 520 2.2 NS 
Cd68 2434 2160 -1.1 NS 2097 6895 3.3 <0.001 586 1451 2.5   NS 500 914 1.8 NS 
Ccl3 303 329 1.1 NS 207 662 3.2 <0.001 111 194 1.7 NS 116 182 1.6 NS 
Emr1 1247 1177 -1.1 NS 1276 3800 3.0 <0.001 283 604 2.1 NS 242 475 2.0 NS 
Ccl2 536 556 1.0 NS 546 1174 2.1 <0.05 158 225 1.4   NS 138 185 1.3 NS 
Ccl9 1457 1691 1.1 NS 1529 3262 2.1 <0.01 347 780 2.2 NS 249 467 1.8 NS 
Tnfrsf1b 911 735 -1.2 NS 682 1183 1.7 <0.01 226 304 1.3 NS 184 256 1.4 NS 
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Thoracic PVAT and interscapular BAT are relatively resistant to 
macrophage infiltration under HFD conditions.   
In order to directly test the extent of macrophage infiltration into BAT and 
PVAT, we immunostained sections of SAT, VAT, BAT and PVAT from the 
thoracic aorta for the macrophage marker F4/80 (Figure 3.5).  Feeding mice a 
HFD for 13 weeks resulted in significant macrophage infiltration in VAT and SAT, 
as expected (Figure 3.5 B, D). In contrast, little or no F4/80 staining was detected 
in BAT or PVAT from these same mice (Figure 3.5 F, H).  In order to test whether 
a longer duration of HFD would result in inflammation of BAT or PVAT, we 
continued HFD for 20 weeks in a second cohort of animals (Fig. 6).  Again, 
visceral fat showed abundant macrophage infiltration (Figure 3.6 D), but despite 
marked enlargement and coalescence of lipid droplets in BAT and PVAT, 
macrophages were absent (Figure 3.6 F, H).  The same results were obtained 
after staining BAT and VAT from animals fed a HFD for 20 weeks with a second 
macrophage marker, CD68 (Data not shown). 
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Figure 3.5: PVAT and BAT are resistant to inflammation after 13 wk of HFD. 
SAT (Aand B), VAT (C and D), BAT (E and F), and PVAT (G and H) from the 
aortic arch was harvested from lean and obese mice (n = 3 per group). Samples 
were fixed in 4% formalin, sectioned, and stained with a rat anti-mouse F4/80 
primary antibody (ABd Serotec). Staining was visualized with a horseradish-
peroxidase-linked rabbit anti-rat secondary antibody. Abundant macrophages 
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were seen predominantly in VAT, but also SAT, forming crown-like structures 
(arrowheads). No macrophages were seen in BAT or PVAT (magnification: ×25). 
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Figure 3.6: Perivascular and brown adipose tissue are resistant to 
inflammation after 20 wk of HFD. A second cohort of mice was continued on 
HFD for 20 wk. SAT (A and B), VAT (C and D), BAT (E and F), and PVAT 
(G and H) from the aortic arch was harvested from lean and obese mice (n = 3 
per group). Samples were fixed in 4% formalin, sectioned, and stained with a rat 
anti-mouse F4/80 primary antibody (ABd Serotec). Staining was visualized with a 
HRP linked rabbit anti-rat secondary antibody. Again, abundant macrophages 
were seen in VAT (D). No macrophages were seen in BAT (F) or PVAT (H) 
despite distortion and enlargement of lipid droplet morphology (magnification: 
×25). 
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FACS analysis confirms prolonged HFD in mice results in little macrophage 
infiltration of BAT compared to VAT. 
In order to better characterize the levels of macrophage accumulation in 
VAT versus BAT, we performed FACS analysis on the stromal vascular fraction 
(SVF) of collagenase digested adipose tissue from VAT and BAT in ND and HFD 
conditions.  CD68 and F4/80 markers define total macrophage populations in 
adipose tissue, but do not differentiate between cells at various levels of 
activation [106, 194, 237].   Therefore, after exclusion of CD31+ endothelial cells 
from the SVF, we chose to doubly stain cells for CD11b and CD11c, the latter 
being a marker of classical (M1) macrophage differentiation [237].  Eleven weeks 
of HFD resulted in a striking and significant enrichment of CD11b+/CD11c+ 
macrophages in VAT compared to that observed for BAT (31.7% vs. 1.03%)(Fig. 
7A).  As we failed to observe macrophage recruitment into BAT with 11 weeks of 
HFD, we extended the duration of the HFD to 20 weeks (Figure 3.7B).  This 
prolonged HFD duration resulted in a marked, significant increase in 
CD11b+/CD11c+ macrophages in VAT, while BAT showed no enrichment of this 
cell population.  Unfortunately, we were unable to perform FACS on PVAT due to 
the small quantity of this tissue in the aortic arch.  However, the results of FACS 
analysis confirm that VAT is enriched with M1 macrophages after 11 and 20 
weeks of HFD, while BAT was resistant to this effect. 
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Figure 3.7: BAT is resistant to inflammation after 11 and 20 wk of HFD. A: 
after 11 wk of HFD, the stromal vascular fraction was isolated from VAT and BAT 
and stained with CD31-PE, CD11b-PerCp Cy5.5, and CD11c-PE Cy7. Samples 
were analyzed on a LSRII flow cytometer, gating for CD31-negative cells. High-
fat feeding resulted in a significant increase in the percentage of CD11b- and 
CD11c-positive cells in the SVF of visceral but not brown adipose (31.7 vs. 
1.03%). B: similar results were obtained after 20 wk of HFD. Results represent 3 
independent experiments.  
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DISCUSSION 
A major finding of the present studies is that PVAT from the murine 
thoracic aorta displays a gene expression pattern that is nearly identical to 
interscapular BAT (Fig. 3.4, Table 3.1).  The similarity of gene expression 
between PVAT and BAT includes identical expression levels of the brown 
adipocyte genes Cidea, Ucp-1, Dio2, and Prdm16.  Only 0.79% of genes 
represented on chip were differentially regulated between PVAT and BAT in 
normal diet conditions at the stringency level used.  Interestingly, immunoglobulin 
genes were expressed to a greater extent in PVAT; this has also been 
demonstrated in human coronary PVAT [238].  We hypothesize that this due to 
the presence of vascular associated lymphoid tissue [239], although we have 
been unable to visualize such tissue using B cell specific markers (Data not 
shown).   
In contrast to these subtle differences between PVAT and BAT, major 
differences between PVAT and WAT were observed in the expression of genes 
previously shown to be highly and selectively expressed in brown or white 
adipose tissues (Table 3.1). Our data thus clarify and definitively substantiate 
previous indications that mouse thoracic PVAT is similar to BAT[25, 26, 225].  
Importantly, these previous studies demonstrate  that PVAT can have 
characteristics of both BAT and WAT, but this dichotomy largely depends upon 
the anatomical context; that surrounding the abdominal aorta resembling WAT 
and that surrounding the thoracic aorta BAT [26, 225].  Our studies directly 
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comparing thoracic PVAT gene expression (Table 3.1, and Figure 3.4) and 
histological appearance (Figure 3.2) to mouse intrascapular BAT show 
unequivocally that these two adipose depots are virtually identical.  This appears 
different from human coronary PVAT which demonstrates an intermediate 
phenotype between white and brown adipose [222].   
After 13 weeks of high fat feeding, VAT displayed the expected dramatic 
increase in expression of many immune cell enriched genes, while thoracic 
PVAT and BAT did not. This was somewhat surprising because some previous 
reports indicated that increased infiltration of macrophages and T cells into both 
PVAT [220, 225, 226] and BAT [92, 240] could be detected in mouse models.  Xu 
et al. reported that genetic and diet induced obesity resulted in chronic 
inflammation in WAT but not BAT[194]. Thus the extent of BAT inflammation may 
greatly depend upon the mouse strain and conditions used. Our data are 
consistent with the results of Xu et al. suggesting BAT is comparatively resistant 
to inflammation in C57BL6/J mice after HFD feeding.   
In contrast to our present findings of very low inflammation of PVAT in 
mice after 13 weeks of HFD, some investigators have proposed that PVAT is an 
intrinsically pro-inflammatory depot [222, 224, 238].  For example, humans with 
established coronary artery disease have higher mRNA and protein levels of IL-
1β, IL-6, MCP-1, and TNFα in epicardial adipose than in paired SAT samples.  
More recently, Chatterjee et al. published data regarding human coronary PVAT 
and murine thoracic PVAT, the same  anatomic fat depot we have studied here.  
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In control mice, relative mRNA expression of Acrp30, Pparγ and Fabp4 was 
lower in PVAT than SAT.  With two weeks of HFD feeding, expression of these 
adipocyte specific genes further declined, while expression of the pro-
inflammatory genes Lep and Mip1α increased [222]. The authors concluded that 
in comparison to SAT, PVAT was poorly differentiated and intrinsically pro-
inflammatory, and hence possibly an etiologic factor in the development of 
vascular disease [222].   
Our findings are in contrast to the above [222] in that expression of Acrp30 
and Pparγ2 was not different in thoracic PVAT compared to other fat depots.  A 
possible explanation for the difference in expression of Acrp30 and Pparγ2 
between the two studies is that there may be diet or age dependent changes in 
the expression of these two genes; Chatterjee et al. used a shorter duration HFD 
and younger mice [222].  For example, it may be that younger and older mice 
than those studied herein (21 weeks) are prone to inflammation of PVAT.  Two 
studies which have reported obesity associated inflammation of abdominal and 
femoral PVAT, used 40 week and 22 week old mice respectively[225, 226].  
Therefore it is likely that many factors including age, strain, diet, and specific 
anatomic location influence whether or not PVAT becomes inflamed.  Finally, 
although they did not report expression of BAT genes in their mouse model, their 
failure to observe significant expression of immune cell specific genes Cd68 and 
Cd3 by qPCR does concur with our results [222].   
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Importantly, both we and Chatterjee et al. have studied PVAT from the 
thoracic aortic arch, as this a segment of the aorta prone to atherosclerosis both 
in humans and mice [222].  Although PVAT was originally hypothesized to signal 
in a “vasocrine” fashion to influence vascular tone [23], it has subsequently been 
implicated in adventitial inflammation which might promote atherosclerosis [23, 
220, 222, 224, 238]; our study was designed to test these latter hypotheses. 
The overall evidence from the literature combined with our present work 
suggests that PVAT can have different characteristics depending upon its 
anatomical location. Thus BAT-like adipose surrounds the thoracic aorta and 
WAT surrounds the abdominal aorta [26, 225].  As such, we suggest that PVAT 
surrounding the abdominal aorta, like its visceral fat counterpart, is prone to the 
dysregulated adipocyte biology of obesity and subsequent inflammation.  This 
idea has been verified by Takaoka et al., who demonstrated that PVAT 
surrounding the femoral artery is WAT that has beneficial properties in lean 
conditions which are mediated by the paracrine effects of adiponectin 
(Acrp30)[226].  In obese states, inflammation and macrophage infiltration of 
PVAT surrounding the femoral artery results in decreased adiponectin secretion 
and increased Tnfα expression, both of which facilitate pathological neointimal 
hyperplasia in response to vessel injury [226].  In humans, neointimal hyperplasia 
contributes to the pathophysiology of coronary artery disease.  For example, 
diabetes and obesity are associated with increased rates of in-stent restenosis 
following percutaneous intervention (PCI) due to neointimal hyperplasia [241].    
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A  scenario in which white PVAT is beneficial in lean conditions, but becomes 
dysfunctional in obese conditions, is analogous to the current model of obesity 
induced insulin resistance [8]. These and other reports support the concept that 
PVAT with white adipose features conforms to this model [223, 225, 226, 242].  
The important contribution of our work is that brown PVAT surrounding the 
thoracic aorta appears to be resistant to obesity induced inflammation, and 
hence may offer protection from the associated changes to the arterial adventitia.   
The finding that PVAT and BAT display little or macrophage infiltration 
under HFD conditions, while WAT does, raises the interesting question: what is 
unique to WAT that causes infiltration of macrophages?  A recent paper by 
Kosteli et. al may shed insight into this important question [80].  Using caloric 
restriction of previously HFD fed mice, the authors showed that rates of 
adipocyte lipolysis correlate with macrophage infiltration.  These studies suggest 
that the chronic elevation in WAT lipolysis observed in obesity causes increased 
release of fatty acids, which serve to stimulate macrophage infiltration [80].  This 
hypothesis offers a potential explanation for why BAT and BAT-like PVAT fail to 
attract immune cells. The unique function of BAT and PVAT to rapidly metabolize 
fatty acids via high capacity for  beta-oxidation likely results in relatively low rates 
of local free fatty acid release from the cells in comparison to WAT [243].  A 
second possibility, is that the fatty acid species released by BAT and PVAT may 
also afford an anti-inflammatory effect. The ratio of saturated to polyunsaturated 
fatty acids has been shown to increase in the VAT and abdominal PVAT of high 
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fructose fed rats [244]. Thus under these conditions WAT may release relatively 
higher levels of saturated fatty acids, which may be more active in stimulating 
macrophage chemotaxis [79, 245].  Finally, abdominal or white PVAT may 
secrete pro-inflammatory adipokines or cytokines.  We have found that although 
white adipose (SAT, VAT) has greater expression of adiponectin, which has anti-
inflammatory effects, it also has greater mRNA expression of adipokines which 
correlate with vascular disease (Rbp4, Resistin)(Table 3.1)[246, 247].  
Furthermore, abdominal PVAT has been shown to secrete greater amounts of 
the chemokine MCP-1 than thoracic PVAT; our data also confirm that Mcp-1(Ccl-
2) mRNA is increased in VAT but not thoracic PVAT after high fat feeding (Table 
3.2)[225].  The comparatively greater diameter of white adipocytes in VAT and 
abdominal PVAT may be one factor responsible for increased Mcp-1 
transcription [248, 249].  
  In summary, results from this present study demonstrate that PVAT 
surrounding the thoracic aorta is effectively BAT, as shown by light and electron 
microscopy, and full genome expression analysis. Thoracic PVAT and 
interscapular BAT are resistant to inflammation induced by 13 and 20 weeks of 
HFD, as shown by reduced expression of immune cell enriched genes, 
immunohistochemistry with macrophage markers, and FACS analysis for 
activated macrophages.  This work provides an important mandate to study 
expression of BAT genes in human PVAT from patients with and without vascular 
disease.  In light of the recent discovery of functional BAT in adult humans, and 
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given the known beneficial metabolic and herein described anti-inflammatory 
properties of BAT, promotion of a BAT phenotype in the perivascular niche may 
have important effects in preventing vascular diseases such as hypertension and 
atherosclerosis. 
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CHAPTER IV: DISCUSSION 
 The correlation between obesity and inflammation has been well-
described. Obese adipose tissue is characterized by local inflammation and 
obese individuals have elevated serum markers of inflammation [90, 95, 101, 
110, 115, 120, 174, 195, 218, 250-255]. Numerous molecules are secreted from 
obese adipose tissue, and these molecules modulate local and systemic insulin 
resistance. Locally, these molecules decrease adipocyte insulin response and 
increase FFA release into circulation [256]. Systemically, these molecules and 
the increased FFAs are able to impair insulin responsiveness in other insulin 
target tissues such as the liver and skeletal muscle. Attempts to delineate the 
individual roles of these inflammatory molecules have been made and numerous 
knockout mice have been created and challenged with a HFD.  
 
 In the second chapter of this thesis, we characterized one such molecule, 
CD40, and its role in adipose tissue inflammation and insulin resistance. We 
found that CD40-/- mice were smaller, had decreased physical activity and food 
intake on HFD. Surprisingly, despite their decreased size, knockout mice were 
more insulin resistant as measured by glucose tolerance test (GTT) and insulin 
tolerance test (ITT) and a hyperinsulinemic-euglycemic clamp study found 
decreased glucose uptake in BAT with no changes to glucose uptake in WAT or 
muscle. Additionally, we found that CD40-deficient mice had increased hepatic 
steatosis on HFD likely due to increased lipolysis from WAT and increased de 
novo lipogenesis in the liver. These steatotic livers were more insulin resistant as 
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measured by Akt phosphorylation following intraperitoneal insulin injection and 
had increased gluconeogenesis as determined by rtPCR and PTT despite 
decreased inflammation by rtPCR. Increased lipolysis in visceral fat was likely 
due to increased inflammation in epididymal adipose tissue as defined by 
macrophages, inflammatory T cells, B cells, NK, NKT cells and eosinophils as 
well as rtPCR. The CD40 knockout mouse is therefore an interesting model of 
hepatic steatosis and insulin resistance in the absence of hepatic inflammation. 
 In the third chapter of this thesis we established that PVAT is similar to 
BAT in gross morphology, gene expression and in terms of resistance to 
inflammation in diet-induced obesity. Inflammation was defined by the presence 
of F480/CD11c+ macrophages and the expression of inflammatory genes by 
rtPCR and microarray. We hypothesize that the lack of inflammation in BAT and 
PVAT is likely due to decreased FFA and/or chemokine release by these tissues 
compared to WAT.  
 The above findings lead to new questions and directions for further work. 
Which cell type or types are involved in CD40 action in the adipose and liver 
phenotypes observed in knockout animals? How can the absence of CD40 lead 
to increased inflammation in adipose tissue and decreased inflammation in liver?  
Which factor(s) are involved in BAT and PVAT's resistance to inflammation and 
how does this inform our knowledge of WAT pathophysiology? Is inflammation in 
PVAT involved in vascular disease, like atherosclerosis? 
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The role of CD40 in diet-induced obesity 
 Our studies suggest that CD40 plays a protective role in metabolic 
disease by attenuating inflammation in diet-induced obesity. Immune cells 
infiltrate obese adipose tissue and contribute to an increasingly pro-inflammatory 
environment. CD40 functions to decrease adipose tissue inflammation and thus 
protects against local and systemic insulin resistance (Figure 4.1). The CD40 
knockout mouse that we used in our studies lacks CD40 on all cells types. 
However, CD40 is expressed on many cell types, and its activation can have a 
myriad of effects depending on the cell and tissue type (Table 1.3).  
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Figure 4.1: Proposed effect of CD40 on adipose tissue inflammation and 
insulin sensitivity. CD40 decreases adipose tissue inflammation thereby 
protecting against systemic insulin resistance in diet-induced obesity.  
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 Increasing adipose tissue inflammation is observed with increasing obesity 
and numerous immune cells have been implicated in the process (Table 1.2).  It 
would be interesting to sort the immune cells involved in normal obesity-induced 
adipose tissue inflammation and measure CD40 expression. The cells that highly 
express CD40 in obese adipose tissue would be targets for further study. B cells, 
monocytes/macrophages, T cells, eosinophils and endothelial cells all express 
functional CD40 and are involved in adipose tissue inflammation. We could 
compare cells from CD40 knockout and WT animals in terms of their activation 
state and response to proinflammatory stimuli. 
 The major shortcoming of these techniques is that, like our study, they are 
observational. They do not distinguish between primary defects in cells caused 
by CD40 deficiency and secondary defects caused by interaction with other 
CD40-deficient cells. The way to determine the cell-specific role of CD40 in DIO 
is to create a conditional knockout mouse that lacks CD40 specifically in one cell 
type using the Cre-lox system. The Cre recombinase is a 38 kDa protein that can 
catalyze the deletion of a DNA segment that is flanked by loxP sites [257]. A 
conditional knockout mouse could be obtained by the crossing of a mouse 
expressing CD40 flanked by loxP sites with a Cre transgenic mouse that is 
specific for the cell of interest. Mice expressing the cre recombinase under the 
control of promoters that are specific for each of these cells are commercially 
available from Jackson Laboratory [258-262]. If cell-specific CD40 is responsible 
for the exacerbated insulin resistance of our knockout mice, then I would expect 
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that conditional knockout mice specific for the cell(s) involved will have a 
phenotype similar to that of our global knockout. These mice would also be 
useful in studying the mechanisms of atherosclerosis and autoimminue diseases. 
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The role of BAT and PVAT in diet-induced obesity  
 Chapter III of this dissertation established that PVAT is similar to BAT in 
morphology and gene expression. The contributions of different fat depots to 
insulin resistance or insulin sensitivity in the context of obesity have been 
extensively characterized. The contrast between SAT and VAT in their role in 
insulin sensitivity in obesity have motivated increased interest in characterizing 
other fat depots that could play a role in metabolic disease. Future studies should 
examine the function and significance of this tissue in obesity-related vascular 
disorders such as atherosclerosis.  
 A major limitation of our study was its observational nature. Unfortunately, 
conditional knockout or transgenic mice targeting the PVAT do not exist because 
PVAT-specific genes have not been identified and there is no current known 
method to induce inflammation specifically in PVAT. Several studies have linked 
PVAT inflammation with vascular disease by transplantation of VAT to the area 
adjacent to major vessels [263]. To further investigate the role of PVAT in 
atherosclerosis, we could utilize the Apoe-/- mouse [264, 265]. The Apoe-/- 
mouse has extremely high plasma cholesterol due to inability to take up 
chylomicron remnants and VLDL [266]. If PVAT inflammation plays a role in 
atherosclerosis progression, I hypothesize that Apoe-/- mice would have PVAT 
inflammation adjacent to atherosclerotic areas of vessels. If this is the case, we 
could investigate which genes are associated with initiating PVAT inflammation 
by looking at gene expression in PVAT over a time course of HFD.  
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Conclusion  
 Obesity is associated with increased local and systemic inflammation, 
which is associated with abnormalities in insulin signaling. We identify CD40 as a 
novel mediator of adipose tissue inflammation that attenuates inflammation in 
adipose tissue during diet-induced obesity. Additionally, in Chapter III of this 
dissertation we report that PVAT is similar to BAT in its morphology and 
resistance to inflammation in obesity. We believe that the work presented here 
provides impetus to further study the role of CD40 in adipose tissue and the 
functional role of PVAT in atherosclerosis in the context of diet-induced obesity. 
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